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INTERACTIONS BETWEEN BONE REMODELING AND MICRODAMAGE IN 
CANCELLOUS BONE 
Jonathan Bradford Matheny, Ph. D. 
Cornell University 2017 
Increases in bone remodeling impair the mechanical performance of cancellous 
bone and are associated with the progression of post-menopausal osteoporosis. Bone 
remodeling is expected to modify cancellous bone strength by changing both bone 
quantity and bone quality. Bone quality refers to factors that influence the mechanical 
performance of bone that are not well explained by bone mass. Here, I investigate how 
bone quality is changed by altering bone remodeling through pharmaceutical treatment 
and how aspects of bone quality affect the accumulation of tissue damage 
(microdamage) in cancellous bone. Finally, I investigate how bone remodeling 
responds to microdamage in a rabbit model of bone marrow lesions (BMLs). 
First, we examine how treatment with anti-resorptive agents influences the size 
of individual resorption cavities. We find that anti-resorptive treatment is associated 
with reductions in the size of resorption cavities in rat vertebral cancellous bone. A 
reduction in resorption cavity size is hypothesized to decrease stress concentrations 
generated by the cavity during loading and thereby reduce the likelihood that damage 
will form nearby. 
Next, we determine how treatment with sclerostin antibody modifies the 
trabecular morphology (shape and orientation of individual trabeculae) in a 
cynomolgus monkey model. We find that sclerostin antibody increases bone formation 
 iv 
leading to a conversion of rod-like trabeculae into plate-like trabeculae and increases 
thickness of both rods-like and plate-like trabeculae leading to an increase in apparent 
stiffness, as predicted using finite element models. Although microarchitecture was 
modified, the improvements in apparent stiffness were well explained by changes in 
bone mass suggesting that treatment changes bone mass and not bone quality. 
We then examine how resorption cavities and tissue composition influence 
where microdamage forms and propagates in cancellous bone submitted to cyclic 
mechanical loading. We find that microdamage formed preferentially in the interior 
regions of cancellous bone and distant from trabecular surfaces and resorption cavities. 
The interior regions of trabeculae experience lower stresses but are composed of more 
brittle tissue. 
Finally, we investigate the bone remodeling response to microdamage in an in 
vivo loading model. We find an increase in bone resorption in response to load-
induced microdamage. Cancellous bone from within the bone marrow lesion displayed 
microdamage and increased bone resorption. 
In summary, tissue composition of cancellous bone influences cancellous bone 
mechanics. Resorption cavities, while clearly generating stress concentrations do not 
influence microdamage accumulation. However, when microdamage does form within 
cancellous bone there is a focal increase in bone resorption. 
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CHAPTER 1                                                     
INTRODUCTION 
 
1.1. Bone 
Bone is present in two forms in the body, cortical and cancellous bone (Figure 
1.1A). Cortical bone forms the outer layer of whole bones. Cortical bone has an 
ultrastructure that includes cylindrical lamellar structures known as osteons. Tissue in 
between osteons is known as interstitial bone. Cancellous bone, sometimes referred to 
as trabecular bone, is an open-cell foam network of trabeculae that is present at the 
ends of long bones as well as in the interior of short bones and vertebrae (Figure 
1.1B). Cancellous bone tissue includes lamellar structures known as hemisosteons or 
“trabecular packets” and also contains interstitial bone between hemiosteons. 
Compared to cortical bone, cancellous bone has a greater surface to volume ratio and 
significantly greater porosity than cortical bone and displays relatively large (~1mm) 
spaces between trabeculae (~100 μm thick). Cancellous and cortical bone tissue are 
composed of Type I collagen fibers and nanometer sized mineral platelets of impure 
hydroxyapatite and water [1-3]. Both cortical bone and cancellous bone undergo a 
process known as bone remodeling to repair and replace bone tissue.  
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Figure 1.1. (A) A schematic showing cortical and cancellous bone in a cross-section 
of the proximal femur is shown. (B) A close up region of cancellous bone displaying 
an open-cell network of trabeculae is shown. Image in (A) adapted from Hernandez et 
al. [4]. 
1.2. Bone Remodeling and Bone Modeling 
There are two ways in which bone cells modify bone volume: bone remodeling 
and bone modeling. Bone remodeling is a biological process in which discrete regions 
of bone tissue are removed by osteoclasts and replaced with new bone tissue 
synthesized by osteoblasts. The adult skeleton is in a continual state of bone 
remodeling; discrete locations of bone remodeling are present on the surfaces of trabeculae in 
cancellous bone as well as within osteons in cortical bone [5]. The complete resorption-
formation process at one location lasts 6-9 months [6]. While bone remodeling always 
involves resorption followed by formation, bone modeling involves either resorption 
or formation. Bone modeling occurs during bone growth, following changes in 
mechanical loading, or due to pharmaceutical intervention (See Anabolic Drug 
Treatment) [6, 7]. The volume of bone both resorbed and formed over a period of time 
is referred to a bone turnover and can be estimated using serum biomarkers of bone 
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formation and resorption [8]. Both bone remodeling and modeling are regulated by 
osteocytes. Osteocytes are cells located inside lacunae within bone tissue and form a 
network connecting each other and lining cells on bone surfaces. The processes 
involved in bone remodeling and modeling are described below (See Figure 1.2 for 
schematic of bone remodeling). 
 
Figure 1.2. A schematic of bone remodeling is shown. Osteoclasts (pink) remove 
bone tissue, forming a resorption cavity. Osteoblasts (light blue) fill in the cavity with 
newly formed bone (shown in purple). Osteocytes (dark blue) communicate with 
lining cells (green) to regulate bone remodeling 
 1.2.1. Bone Resorption by Osteoclasts 
The first step of the bone remodeling process is activation of osteoclasts [5]. 
Osteoclasts are derived from monocyte/macrophage precursor cells (granulocyte–
macrophage colony-forming units) by the cytokine receptor activator of nuclear factor 
kappa-B ligand (RANKL). Osteoclastogenesis can be controlled by osteoblast/stromal 
cells through modification of the ratio of RANKL to osteoprotegerin (OPG, a RANKL 
inhibitor). Osteoclast differentiation is also regulated by interleukin-6 and -11 (IL-6 & 
IL-11) secreted by osteoblastic progenitor cells. The activation of RANK by RANKL 
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polarizes osteoclasts to resorb bone [9]. Activated osteoclasts attach to bone surfaces 
and release hydrochloric acid to break down the mineral component of bone and 
proteases to degrade the organic component of bone, leaving a resorption cavity [5, 9-
11]. Osteoclasts can regulate bone remodeling by releasing transforming growth factor 
beta 1 (TGF-β) as bone is resorbed. TGF-β promotes osteoclast apoptosis and 
stimulates bone formation [12-15]. The period of bone resorption by osteoclasts at one 
location lasts 2-3 weeks in humans, after which osteoclasts undergo apoptosis [16].  
1.2.2. Bone Formation by Osteoblasts 
Osteoblasts are derived from mesenchymal stem and progenitor cells [17]. 
Osteoblast differentiation is promoted by a number of transcription and signaling 
factors, such as runt-related transcription factor-2 (Runx2), Osterix (Osx) and the low-
density lipoprotein-receptor-related protein 5 (LRP5) by activating Wnt. After 
activation, Wnt increases levels of β-catenin in mesenchymal stem cells leading to 
differentiation into osteoblasts [6, 12, 16, 18, 19]. Mature osteoblasts produce and lay 
down new bone matrix (Type I collagen and non-collagenous proteins) filling in 
resorption cavities over a period of 3 months. Following bone formation, osteoblasts 
will either undergo apoptosis or differentiate into lining cells or osteocytes [6, 12]. 
1.2.3. Regulatory Function of Osteocytes 
Osteocytes, derived from osteoblasts, serve a powerful regulatory function in 
bone. Osteocytes regulate how much bone mineral is deposited through production of 
Dentin Matrix Acidic Phosphoprotein 1 (DMP1), Matrix Extracellular 
Phosphoglycoprotein (MEPE) and Phosphate-Regulating Neutral Endopeptidase, X-
Linked (PHEX). Osteocytes are mechanosensitive cells that regulate bone 
  
22 
 
modeling/remodeling. Osteocytes secrete sclerostin, a molecule which inhibits the 
Wnt pathway. By regulating Wnt signaling, osteocytes increase/decrease bone 
formation via production of sclerostin. Osteocytes also stimulate bone resorption from 
osteoclasts (summarized in [20]). When microdamage is formed in bone, the 
osteocytes in the immediate vicinity of microdamage undergo apoptosis. The viable 
osteocytes surrounding the microdamage then express RANKL to recruit osteoclasts 
to the area to resorb the damaged bone [21, 22]. The relationship between 
microdamage and subsequent bone resorption has been shown in cortical bone but 
only hypothesized in cancellous bone (For further details on microdamage, see 
Identification and Measurement of Microdamage in Bone).  
1.3. Osteoporosis and Fracture risk 
Osteoporosis is a disease characterized by a reduction in bone mass. 
Osteoporosis affects over 10 million people, resulting in 1.5 million fractures per year 
in the United States and healthcare costs estimated to be $12-18 billion dollars per 
year [23, 24]. Most osteoporosis-related fractures involve minimal to no trauma [25] 
and are referred to as fragility fractures. The most common way to identify individuals 
with osteoporosis is through the measurement of bone mineral density (BMD) using 
dual x-ray absorptiometry. A person with a BMD that is 2.5 standard deviations below 
the reference population meets the clinical diagnosis of osteoporosis [23, 26]. BMD is 
influenced by bone volume, shape and tissue mineral density [27]. BMD is closely 
related to fracture risk but other factors also contribute to fracture risk including 
increased bone remodeling, estrogen depletion in post-menopausal women, and age 
[28-31]. Pharmaceutical treatments known as “anti-resorptive treatments” reduce the 
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amount of bone turnover and are therefore useful in preventing osteoporosis-related 
fractures. 
1.5. Osteoporosis Treatments 
Current osteoporosis drug treatments are classified as either anti-resorptive or 
anabolic based on their method of action.  
1.5.1. Anti-Resorptive Drug Treatment 
Anti-resorptive treatments for osteoporosis decrease the rate of bone 
remodeling, reducing bone turnover and preserving the existing bone microstructure. 
Two examples of anti-resorptive drugs are selective estrogen receptor modulators 
(SERMs) and bisphosphonates. Estrogen plays an important role in bone development 
and maintenance by suppressing bone remodeling. When circulating estrogen is 
depleted after the menopausal transition, the rate of bone remodeling is increased. 
Increases in bone turnover from remodeling causes bone loss by increasing bone 
resorption, perforating trabeculae by resorption events, and decreasing bone volume 
formed in each remodeling cycle [6, 12, 17, 32-34]. Raloxifene is a SERM used to 
treat osteoporosis and is an antagonist to estrogen-receptor-β and a partial agonist to 
estrogen-receptor-α. In patients treated with raloxifene, vertebral fractures rates are 
reduced by 30-50%, spinal BMD is increased (2-3%) and biomarkers of bone turnover 
are decreased by 20-40% [35, 36]. Bisphosphonates, such as risedronate, inhibit bone 
remodeling by disrupting the function of osteoclasts. Bisphosphonates bind to 
hydroxyapatite present on bone surfaces. When a bone surface containing 
bisphosphonates is resorbed, the bisphosphonate is consumed by the osteoclast and 
then inhibits the GTPases that regulate osteoclast cytoskeletal rearrangement, 
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impairing the cell’s ability to resorb bone and eventually leading to apoptosis. 
Bisphosphonates may also inhibit osteoclastogenesis [15, 37, 38]. In patients treated 
with risedronate, vertebral fracture risk is decreased by 41-49%, spinal BMD is 
increased by 5-6%, and serum markers for bone turnover are reduced by 50% [39, 40]. 
While anti-resorptive drug treatments are effective at preventing fractures, there are 
drawbacks to this treatment option. One function of bone remodeling is remove old or 
damaged bone tissue. If bone turnover is inhibited, damaged tissue is less likely to be 
repaired by bone resorption [34]. The increase in tissue age due to inhibited bone 
resorption will also result in tissue with increased tissue degree of mineralization and 
non-enzymatic glycation: two characteristics of bone tissue associated with tissue 
brittleness.  
1.5.2. Anabolic Drug Treatment 
Anabolic drug treatments act to shift the balance of bone remodeling towards 
bone formation. Two examples of anabolic drug treatments are parathyroid hormone 
(PTH) and Sclerostin Antibody (Scl-Ab). PTH (specifically hPTH (1-34) or 
teraperatide) given intermittently increases bone formation by both increasing the rate 
of bone remodeling and increasing the amount of bone formed during each remodeling 
cycle [41]. In patients treated with PTH, vertebral fracture risk is decreased by 65%, 
spinal BMD is increased by 13% and markers of bone turnover are increased by at 
least 100% [42, 43]. Scl-Ab increases modeling-based bone formation and reduces 
bone resorption [7]. In patients treated with Scl-Ab, vertebral fracture risk is reduced 
by 73% and BMD is increased by 13%. Serum markers of bone formation are 
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increased for Scl-Ab and returned to baseline after 9-months of continuous treatment 
while markers for bone resorption were below levels for placebo [44].  
1.6. Bone Remodeling and Bone Quality 
BMD accounts of between 50-80% of whole bone strength and does not fully 
explain fracture risk. One study observed that 82% of postmenopausal women who 
experienced fractures did not meet the diagnostic threshold for osteoporosis based on 
BMD. The additional factors that influence bone strength and fracture risk besides 
bone mineral density appears to be influenced by increased bone turnover due to bone 
remodeling. Clinical studies indicate that biochemical markers for bone turnover can 
predict fracture risk independent of BMD. Furthermore, reductions in fracture risk 
from anti-resorptive treatments, for instance, are greater than would be expected from 
the associated increases in BMD [45, 46]. These clinical studies suggest that bone 
remodeling influences bone strength and fracture risk in ways not explained by bone 
mass. Differences in bone quality may explain the discrepancy between bone 
remodeling, bone mass and fracture risk. 
Bone quality is a poorly defined term often used to refer to factors that 
influence the mechanical performance of bone that are not well explained by measures 
of bone mass or bone mineral density [47]. The primary focus of this thesis is how 
bone quality in cancellous bone is related to fracture risk. Most osteoporosis-related 
fractures occur in regions of the skeleton with high proportions of cancellous bone 
such as the vertebrae and proximal femur (Figure 1.1) [48]. Alterations in bone 
remodeling are expected to affect bone quality in cancellous bone in the following 
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ways: 1) increased bone resorption by osteoclasts could increase the number or size of 
resorption cavities which act as stress risers; 2) increased bone resorption could lead to 
fenestration of existing trabeculae whereas increased bone formation could lead to the 
creation of new trabeculae; 3) increased bone remodeling could lead to alterations to 
the rod- or plate-like morphology or orientation of individual trabeculae through either 
increased bone resorption or formation; 4) alterations in bone turnover could modify 
the age and composition of bone tissue. The factors mentioned above may influence 
pre- or post-yield mechanical properties of cancellous bone independent of bone mass 
and/or influence the location or amount of microdamage accumulation in bone tissue 
[47, 49, 50]. The subsequent sections will detail approaches that are useful in 
measuring aspects of bone quality that are influenced by bone remodeling as well as 
approaches to characterize the mechanical performance of cancellous bone (See 
Figure 1.3). 
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Figure 1.3. (A) Analyses of cancellous bone microstructure are used to determine 
factors that influence bone strength other than bone mass. A cylindrical region of 
cancellous bone microstructure from a vertebra is shown. Aspects of bone quality in 
cancellous bone include: (B) Bone remodeling events (resorption cavity shown as 
scalloped surface), (C) tissue composition (fluorometric measurement of advanced 
glycation end products (AGEs) is shown), (D) trabecular morphology (trabeculae 
shaped as either rods or plates) and orientation (axial, oblique and transversely aligned 
trabeculae). Mechanical characterization may include (E) high-resolution finite 
element models or (F) characterization of microdamage in the trabecular 
microstructure. 
1.7. Identification and Measurement of Bone Remodeling Events  
Bone formation is traditionally measured using two-dimensional dynamic 
histomorphometry. In dynamic histomorphometry, a florescent marker (tetracycline, 
calcein, xylenol orange) is injected into an animal, in vivo. The agent will accumulate 
at regions of newly formed bone matrix at locations where bone formation is active. 
Another agent is then injected some time later. Bone from the subject is then sectioned 
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for analysis and the fluorescent labels appear as thin fluorescent bands in two-
dimensional histological sections. Measurements, such as the percentage of bone 
surface with fluorescent labels and mineral apposition rate (thickness of mineralized 
bone deposited/time in between labels) are made. The amount of bone resorption can 
be quantified in two-dimensions in histology sections by determining the percentage 
of bone surfaces with current or prior resorption (surfaces with irregular topography 
(Figure 1.3B) and is expressed as the percent eroded surface (ES/BS).   
While two-dimensional approaches described above provide valuable 
information about bone remodeling, they cannot describe the number or size of 
remodeling events [51, 52]. Three-dimensional dynamic histomorphometry using a 
three-dimensional data set obtained from serial milling (described in Chapter 2) 
allows for the measurements of the size and number of resorption cavities and bone 
formation events as well as three-dimensional analogs of traditional bone remodeling 
measurements [53]. 
An additional three-dimensional approach to measure bone formation and 
resorption is in vivo, serial microcomputed tomography (microCT) [54-59]. For serial 
microCT, animals are evaluated with high-resolution microCT (10.5 μm) at sequential 
time points. A comparison of both sets of images following three-dimensional image 
registration can identify and measure areas of bone formation and resorption. The 
approach has limited spatial resolution and is therefore only used on the extremities. 
1.8. Characterization of Cancellous Bone Tissue Material Properties 
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Changes in bone remodeling can affect the composition of both the collagen 
matrix and bone mineral content in cancellous bone by altering tissue age. The size 
and morphology of individual hydroxyapatite particles can be measured using 
transmission electron microscopy and small angle X-ray scattering, and the 
crystallinity and texture of bone tissue can be characterized using Fourier transform 
infrared spectroscopy (FTIR). Bone mineral density distribution (BMDD) can be 
accessed in cancellous bone using quantitative microradiography, quantitative 
backscattered electron imaging and synchrotron radiation microCT (SrμCT) [2]. 
Advanced glycation end products (AGEs) are a product of non-enzymatic 
glycation of collagen. Pentosidine is an example of an AGE that forms cross-links 
between collagen fibers [60, 61]. AGEs can accumulate in bone tissue with age and 
have been associated with a decrease in post-yield mechanical properties of cancellous 
bone [62, 63]. Pentosidine can be quantified using high-perfosrmance liquid 
chromatography (HPLC) whereas overall AGE content can be accessed using a 
fluorometric assay (see Figure 1.3C) [60]. 
1.9. Characterization of Trabecular Microstructure  
MicroCT and serial milling allow for three-dimensional analysis of trabecular 
microstructure. Traditional measurements of trabecular microstructure include bone 
volume fraction (volume of bone/ total volume including marrow space), average 
trabecular thickness, trabecular number, trabecular separation (distance between 
trabeculae), degree of anisotropy, and structure model index (SMI, an average 
measurement of trabecular morphology) [53, 64]. One issue that arises with traditional 
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measurements of trabecular microstructure is that most measurements strongly 
correlate with bone volume fraction (a measurement that is also related to the amount 
of bone mass and BMD as measured in patients). As such, traditional microstructural 
measurements are not aspects of bone quality and are of limited usefulness in 
explaining fracture risk independent of bone mass. 
Measurements of the trabecular morphology and orientation can be obtained 
from individual trabecular segmentation (ITS, Figure 1.3D) and have been shown to 
indicate fracture risk, independent of BMD. Measurements made with ITS are also 
correlated with cancellous bone mechanical performance [65]. ITS can classify 
individual trabeculae as rods and plates and also determine the orientation of each 
trabeculae relative to the primary orientation of trabeculae (axial, oblique, transverse). 
Rods and plates are classified using a 3D skeletonization procedure to decompose the 
structure to surfaces (plates) and curves (rods) [66]. Trabeculae in cancellous bone 
from post-menopausal women and fracture patients have thinner trabeculae and fewer 
plate-like trabeculae [67, 68]. 
1.10. Cancellous Bone Mechanical Performance 
Cancellous bone mechanical performance can be evaluated through 
mechanical testing or through finite element modeling. 
1.10.1. Mechanical Testing of Cancellous Bone  
Mechanical testing of cancellous bone can occur at multiple lengths scales to 
understand how different aspects of cancellous bone contribute to biomechanical 
performance [47]. For instance, mechanical testing using atomic force microscopy or 
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nanoindentation is useful for characterizing changes to mechanical properties of bone 
associated with nano-scale changes in bone tissue [2]. Mechanical testing of 
cancellous bone specimens on the scale of 5 mm using a mechanical testing machine 
is most appropriate to understand how changes to cancellous bone microstructure 
influence bone strength. Specimens of cancellous bone are glued within brass end-
caps and placed in the mechanical testing machine. Loading (monotonic or cyclic) is 
applied in either tension or compression to create microdamage [69-71].  
1.10.3. High Resolution Finite Element Models of Cancellous Bone 
High resolution finite element (FE) models generated using three-dimensional 
images of cancellous bone allow for the estimation of bone tissue stresses and strains 
(Figure 1.3E). FE models of cancellous bone have shown good agreement with 
mechanical properties derived from mechanical testing [72, 73]. Microdamage has 
been observed to form preferentially in regions of high strain determined using FE 
models [74, 75]. FE models of cancellous bone indicate that resorption cavities act 
create as stress risers in bone and decrease cancellous bone strength independent of 
bone volume [50, 76, 77]; furthermore, a cavity with a greater depth relative to the its 
local trabecular thickness creates a greater geometric discontinuity and stress 
concentration effect compared to a more shallow cavity [52]. There is evidence from 
non-linear FE models that homogenous models both overestimate and underestimate 
tissue stresses and strains, indicating that tissue composition may play a role in where 
tissue stresses and strains occur [78].  
1.10.2. Microdamage in Cancellous Bone  
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 Microscopic tissue damage in bone is known as microdamage. Microdamage 
occurs in two primary forms: linear microcracks (50-100 μm long) and patches of 
submicroscopic cracks called diffuse damage [79]. The formation of microcracks is a 
fracture resistance mechanism to resist crack growth through a combination of 
intrinsic (ahead of crack tip) and extrinsic (behind crack tip) toughening mechanisms 
[80-83]. Microcracks allow the bone to dissipate energy through localized failure prior 
to overt failure [84, 85]. Still, small amounts of microdamage generated from 
mechanical loading will diminish cancellous bone mechanical properties [70, 71]. 
Microdamage accumulates in vivo as tissue ages [86] and accumulation of bone 
mineral and AGEs are expected to influence microdamage formation [87] as are stress 
risers in bone such as resorption cavities.  
Microdamage is identified through a process of bulk staining. In non-living 
bone tissue, stains penetrate deep into bone tissue and deposit into cracks, Some 
stains, such as lead uranyl acetate (lead UA) and chelating agents like calcein, are site-
specific, binding to calcium ions exposed by the cracks; other stains such as basic 
fuchsin are not site specific [88]. Most analyses of microdamage are done in two-
dimensions using histological sections; however three-dimensional approaches now 
exist to observe and measure microdamage stained with fluorochrome chelating agents 
visualized using serial milling (Figure 1.3F) or with lead UA visualized using 
microCT [89-92].  
1.12. Bone remodeling, Microdamage and Osteoarthritis 
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Bone remodeling also appears to play an important role in the early 
progression of osteoarthritis. Animal models indicate that increased bone remodeling 
in response to mechanical loading (likely to repair microdamage) is involved in a 
pathway that results in bone marrow lesions and eventually cartilage degeneration [93-
96]. Bone marrow lesions manifest as an increase in signal intensity in water sensitive 
magnetic resonance imaging sequences of subchondral cancellous bone. Bone marrow 
lesions are early indicators of (and possible contributors to) early osteoarthritis 
progression [97]. 
1.12. Thesis Aims 
In Aims 1 and 2, I determine if osteoporosis drug treatments can modify aspects of 
bone quality (resorptive cavity size and trabecular morphology) that are expected to 
influence cancellous bone biomechanical performance. In Aim 3, I examine how 
aspects of bone quality (resorption cavities and tissue composition) influence where 
microdamage forms and propagates in cancellous bone following cyclic mechanical 
loading. In Aim 4, I investigate how microdamage formed by in vivo loading of 
cancellous bone influences subsequent bone remodeling in an animal model. 
1.12.1. Aim 1: Determine if anti-resorptive agents have the ability to regulate the 
size of individual resorption cavities. 
Reductions in fracture risk from anti-resorptive treatments are greater than 
would be expected from the associated increases in bone mineral density (BMD) 
caused by treatment [45, 46]. Reductions in bone remodeling are believed to alter bone 
strength by causing reductions in the number and/or size of resorption cavities [98]. 
Alterations in the size of resorption cavities may change their effects as stress risers in 
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cancellous bone or the likelihood that a cavity will fenestrate an individual trabecula 
[49]. In the current study we use an animal model of established estrogen depletion 
and a three-dimensional dynamic bone histomorphometry approach to determine the 
effect of anti-resorptive treatment on: 1) the size of individual resorption cavities 
(including depth, breadth and volume); and 2) the size of individual bone formation 
events. 
1.12.2. Aim 2: Determine the effects of Sclerostin Antibody treatment to transition 
rod-like trabeculae into plate-like trabeculae 
Animal studies have shown that Scl-Ab treatment increases modeling-based 
bone formation while reducing bone resorption [7] leading to increases in bone mass 
and bone strength [99, 100]. Although increases in bone mineral density often result in 
increases in bone strength and resistance to fracture, many osteoporosis treatments 
cause reductions in fracture risk that are greater than expected from changes in bone 
mineral density alone [45, 46]. While anabolic treatments clearly increase bone 
volume fraction, they may also influence aspects of cancellous microstructure that 
influence bone quality [47]. In the current study, we combine ITS with three-
dimensional dynamic bone histomorphometry to determine the changes in the number 
and size of rod-like and plate-like trabeculae in vertebral cancellous bone over an 8-
week period of treatment with sclerostin antibody. 
1.12.3. Aim 3: Determine the factors that influence the formation and propagation 
of microscopic tissue damage created by fatigue loading. 
In bone, tissue level material toughness has been identified as a key 
mechanism in resisting osteoporosis- and age-related fractures [101]. AGEs 
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accumulate in bone tissue over time and have been shown to have a detrimental effect 
on resistance to crack growth and fracture [102-104]. Resorption cavities formed by 
osteoclasts are have been shown to act as stress risers in bone in FE models [50, 76, 
105] and are thought to promote microdamage. Here we investigate whether sites of 
microdamage created by fatigue loading form and propagate preferentially around 
resorption cavities and/or in the regions where AGEs accumulate.  
1.12.4. Aim 4: Develop a platform to study bone marrow lesions and microdamage 
repair by bone remodeling. 
Bone marrow lesions are associated with increased risk of joint degeneration 
leading to total joint arthroplasty [106-108]. Bone marrow lesions have been observed 
in patients prior to clinical symptoms of osteoarthritis and may be a useful diagnostic 
tool or therapeutic target to prevent cartilage degeneration [109-112]. Biopsies of bone 
marrow lesions acquired at the time of total joint arthroplasty show microscopic 
cracks and other tissue damage [113] as well as increased bone remodeling [114], 
woven bone formation, and increased angiogenesis [115]. A pre-clinical model that 
recapitulates the pathogenesis of a bone marrow lesion would be valuable for 
understanding the natural history of bone marrow lesion development and progression. 
Here we establish an animal model of mechanically-induced bone marrow lesions. 
First, we determine whether the loads required to generate microdamage in 
subchondral cancellous bone would also create bone marrow lesions. Second, we 
investigate whether the regions of cancellous bone that receive cyclic loading and 
form bone marrow lesions would correspond with an increase in bone remodeling. 
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CHAPTER 2                                                     
ANTI-RESORPTIVE AGENTS REDUCE THE SIZE OF RESORPTION 
CAVITIES: A THREE-DIMENSIONAL DYNAMIC BONE 
HISTOMORPHOMETRY STUDY 
 
The following chapter was published in Bone in 2013 in Volume 57(1), pgs. 277-283. 
The article is titled “Anti-resorptive agents reduce the size of resorption cavities: A 
three-dimensional dynamic bone histomorphometry study” by Matheny JB, Slyfield 
CR, Tkachenko EV, Lin I, Ehlert KM, Tomlinson RE, Wilson DL, and Hernandez CJ 
and is reprinted here with permission of Elsevier. The animal work in the study 
described was performed under the approval of the Case Western Reserve University 
IACUC. 
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2.1. Abstract 
Alterations in resorption cavities and bone remodeling events during anti-resorptive 
treatment are believed to contribute to reductions in fracture risk. Here, we examine 
changes in the size of individual remodeling events associated with treatment with a 
selective estrogen receptor modulator (raloxifene) or a bisphosphonate (risedronate). 
Adult female rats (6 months of age) were submitted to ovariectomy (n = 17) or sham 
surgery (SHAM, n = 5). One month after surgery, the ovariectomized animals were 
separated into three groups: untreated (OVX, n = 5), raloxifene treated (OVX + Ral, n 
= 6) and risedronate treated (OVX + Ris, n = 6). At 10 months of age, the lumbar 
vertebrae were submitted to three-dimensional dynamic bone histomorphometry to 
examine the size (depth, breadth and volume) of individual resorption cavities and 
formation events. Maximum resorption cavity depth did not differ between the SHAM 
(23.66 ± 1.87 μm, mean ± SD) and OVX (22.88 ± 3.69 μm) groups but was smaller in 
the OVX + Ral (14.96 ± 2.30 μm) and OVX + Ris (14.94 ± 2.70 μm) groups (p < 
0.01). Anti-resorptive treatment was associated with reductions in the surface area of 
resorption cavities and the volume occupied by each resorption cavity (p < 0.01 each). 
The surface area and volume of individual formation events (double-labeled events) in 
the OVX + Ris group were reduced as compared to other groups (p < 0.02). 
Raloxifene treated animals showed similar amounts of bone remodeling (ES/BS and 
dLS/BS) compared to sham-operated controls but smaller cavity size (depth, breadth 
and volume). The current study shows that anti-resorptive agents influence the size of 
resorption cavities and individual remodeling events and that the effect of anti-
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resorptives on individual remodeling events may not always be directly related to the 
degree of suppression of bone remodeling. 
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2.2. Introduction 
Anti-resorptive agents are the most commonly used type of pharmacological 
treatment for osteoporosis. Reductions in fracture risk from anti-resorptive treatments, 
however, are greater than would be expected from the associated increases in bone 
mineral density (BMD) caused by treatment [1, 2].The causes for the disproportionate 
reduction in fracture risk associated with anti-resorptive treatment are not known but 
are commonly attributed to reductions in the amount of bone remodeling in the body. 
Reductions in bone remodeling are believed to alter bone strength by causing 
reductions in the number and/or size of resorption cavities [3]. 
Reductions in bone turnover caused by anti-resorptive agents may occur 
through a reduction in the number of remodeling events, a reduction in the size of 
individual remodeling events (depth, breadth) or both. Alterations in the number and 
size of resorption cavities may change their effects as stress risers in cancellous bone 
or increase the likelihood that a remodeling event will fenestrate individual trabecula 
[4]. Traditional, two-dimensional bone histomorphometry does not differentiate 
between a reduction in the number of individual remodeling events and a reduction in 
the size of individual remodeling events, but differences in number and size represent 
distinct differences in bone biomechanics [4, 5]. 
There are differences among anti-resorptive treatments that have the potential 
to alter bone biomechanical performance. Allen and colleagues found that dogs treated 
with raloxifene showed greater increases in vertebral bone strength per unit bone 
mineral density than untreated animals or animals treated with more potent anti-
resorptive agents (alendronate) [6]. That raloxifene was associated with increased 
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bone strength per unit BMD as compared to animals with greater rates of bone 
turnover (untreated controls) as well as animals with less bone turnover (alendronate 
treated) suggests that the biomechanical effects of anti-resorptive treatments may 
differ, independent of BMD and the degree to which they reduce bone turnover. 
Although changes in tissue material properties are likely a contributor to changes in 
biomechanical properties independent of BMD, alterations in the size of resorption 
cavities/remodeling events may also contribute to changes in cancellous bone 
biomechanics [7]. 
Studies using two-dimensional histomorphometry have reported that anti-
resorptive treatment is associated with a reduction of resorption cavity size [8-15]. 
Although two-dimensional measures of average cavity depth (erosion depth, E.De) in 
a specimen are well established, the technique has been criticized and has been limited 
to a few practitioners [16]. Measures of the surface area of individual resorption 
cavities and formation events estimated from simple perimeter measures in two-
dimensional sections violate stereological assumptions and are therefore biased [17] 
(see [18] for more discussion of the limitations of two-dimensional measures of 
resorption cavities). Recently, we applied a three-dimensional dynamic bone 
histomorphometry approach to the ovariectomized rat, and found that established 
estrogen deficiency in rats is associated with a reduction in the number of resorption 
cavities and formation events in vertebral cancellous bone, but not changes in the size 
of individual resorption cavities (including cavity width and depth) and few changes in 
formation event size [19]. To the authors' knowledge, no studies have used three-
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dimensional imaging to assess the size of resorption cavities and formation events in 
animals treated with anti-resorptive agents. 
Given our previous observation that the size of resorption cavities is not altered 
by a state of estrogen depletion (ovariectomy), we expect that a selective estrogen 
receptor modulator (raloxifene) will not have an effect on the size of resorption 
cavities. In contrast, we expect that a bisphosphonate (risedronate) will reduce the size 
of resorption cavities in three-dimensions because bisphosphonates have direct effects 
on osteoclasts. The long-term goal of the current line of investigation is to understand 
how changes in bone turnover influence bone biomechanics and fracture risk. In the 
current study we use an animal model of established estrogen depletion and a three-
dimensional dynamic bone histomorphometry approach to determine the effect of anti-
resorptive treatment on: 1) the size of individual resorption cavities (including depth, 
breadth and volume); and 2) the size of individual bone formation events. 
2.3. Materials and Methods 
2.3.1. Image Acquisition and Processing 
A total of 22, six month old female Sprague–Dawley rats were subjected to 
either bilateral ovariectomy (n = 17) or sham surgery (SHAM, n = 5). After allowing 
bone loss for one month, the ovariectomized animals were divided into three groups: 
no treatment (OVX, n = 5), or three months of treatment with raloxifene (OVX + Ral, 
n = 6) or risedronate (OVX + Ris, n = 6, Figure 2.1). Raloxifene and risedronate were 
selected because they characterize two different classes of anti-resorptive treatment 
(SERM and bisphosphonate). Raloxifene was selected as it is the only SERM 
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currently used clinically for the treatment of osteoporosis, while risedronate was 
selected because it is a less potent anti-resorptive agent than other bisphosphonates, 
allowing for a more direct comparison to raloxifene. Raloxifene (Sigma-Aldrich, St. 
Louis, MO, USA) was dissolved in deionized water at 1 g/mL and dosed at 1.5 mg/kg, 
3 × per wk. by oral gavage. Risedronate (Proctor & Gamble, Cincinnati, OH, USA) 
was dissolved in deionized water at 0.1 mg/mL and dosed at 5 μg/kg, 3 × per wk. by 
subcutaneous injection (see Figure 2.1). Dosages of raloxifene and risedronate for rats 
were recommended by pharmaceutical companies (Eli Lilly and Co., Indianapolis, IN, 
USA, Proctor & Gamble) to simulate clinical doses for the treatment of 
postmenopausal osteoporosis. Animals were subjected to bone formation double 
labeling with xylenol orange (90 mg/kg) followed by calcein (10 mg/kg) at 10 and 3 
days before euthanasia. Ovariectomy was confirmed using measures of uterine mass. 
Animals from the SHAM and OVX groups were described in a previous publication 
[19]. Animal use was performed under IACUC approval. 
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Figure 2.1. The timing of surgery and treatment in the study design are illustrated. 
Following euthanasia, the lumbar vertebrae were dissected free of soft tissue. 
The cranial and caudal endplates of one lumbar vertebra from each animal (L3 or L4) 
were removed with a low-speed diamond saw and the marrow was washed out using a 
low pressure water jet. The undecalcified vertebrae were then embedded in opaque 
methyl-methacrylate and three-dimensional images of the vertebrae were collected 
using serial milling, as previously described [19, 20]. Serial milling involves 
repeatedly removing the top 5 μm from a plastic embedded specimen and collecting a 
mosaic of images of the newly revealed block face using epifluorescence microscopy. 
In the current study, serial milling was used to collect three fluorescent images (one 
for bone and one for each of the two bone formation labels) at a voxel size of 0.7 × 0.7 
× 5.0 μm [19]. Raw images collected using serial milling occupied 290–390 GB per 
specimen. Pre-processing steps were performed to tile the mosaic, to crop the raw 
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image to the size of the specimen and to remove noise caused by fluorescent signal 
originating beneath the optical plane [20]. Images were manually thresholded to obtain 
binary images of bone and each of the two bone formation markers (xylenol orange 
and calcein). A region of interest more than 1 mm from the growth plate and 1 mm × 1 
mm × 2 mm (height) in size was selected from the center of the vertebral body on the 
caudal side. The region of interest size has been shown to be sufficient for 
characterizing remodeling in a specimen using three-dimensional dynamic bone 
histomorphometry [19]. 
2.3.2. Three-dimensional measurements of bone remodeling 
Three-dimensional measures of resorption cavities were achieved through 
manual tracing by a trained observer. Because manual tracing of resorption cavities in 
three-dimensional images is labor intensive, only a subset of all resorption cavities 
were examined using the following sampling strategy [18]: six independent uniform 
random transverse slices from each specimen were selected (each slice 300 μm from 
the next). An observer identified all eroded surfaces within a slice and the location of 
the eroded surface was recorded. A three-dimensional image of the neighborhood 
surrounding each identified eroded surface was displayed and the resorption cavity 
was traced in the three-dimensional image [21] (Figure 2.2). Our method achieved a 
sampling of 8–32 resorption cavities in each specimen. A three-dimensional spline 
was fit over the cavity to estimate the bone surface existing before resorption began to 
allow automated measures of cavity depth [19]. The mean and maximum depth of 
each cavity was determined. Cavity surface area (the area traced by the observer) and 
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cavity volume were also determined. Three-dimensional dynamic bone 
histomorphometry was used to measure the number and surface area of individual 
formation events (double-labeled) and to measure mineral apposition rate in the three-
dimensional images (See Figure 2.3 for three-dimensional images of cancellous bone 
specimens with bone formation labels) [19]. Following standard sampling rules 
formation event size was measured only in formation events entirely within the region 
of interest. A total of 7–82 double-labeled formation events entirely within the region 
of interest were measured in each specimen. Interobserver repeatability using these 
techniques has been previously characterized [19-21]. 
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Figure 2.2. Resorption cavities were identified as eroded surfaces in gray scale images 
(A) after examination at 2 × magnification (B). Cavities were visualized in three-
dimensions (C) and traced by a trained observer using gray scales images and the 
three-dimensional surface (D). 
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Figure 2.3. Three-dimensional images of cancellous bone from the rat lumbar 
vertebrae for the four groups are shown with transparency to show regions of the first 
bone formation label (xylenol orange) and the second formation label (calcein green). 
The eroded surface in the entire specimen (ES/BS) was measured using line 
intersection counting in two-dimensional sections (the six transverse cross-sections, 
grid with lines spaced 50 μm apart). Additionally, the percent double-labeled surface 
(dLS/BS) was calculated from the three-dimensional images. Three-dimensional 
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measures of bone microarchitecture (BV/TV, Tb.Sp, etc.) were measured using BoneJ 
after coarsening images to 5.0 × 5.0 × 5.0 μm voxels [22]. 
Differences in bone microarchitecture, dLS/BS, MS/BS, BFR/BS and ES/BS 
among the four groups (SHAM, OVX, OVX + Ral, OVX + Ris) were identified with 
the non-parametric Kruskal–Wallis technique using Dunn's multiple comparisons test. 
Differences in formation event or resorption cavity size among groups were 
determined using a generalized least squares regression model to perform ANOVA 
including donor as a random effect to account for repeated measures within each 
animal (i.e. multiple formation events and cavities within each specimen). Multiple 
comparisons were performed using the Holm post-hoc test. 
2.4. Results 
At four months after surgery, ovariectomized animals showed reduced bone 
volume fraction and bone-specific surface as compared to sham-operated controls (p < 
0.05). Ovariectomized animals treated with raloxifene for three months showed 
reduced eroded surface (ES/BS) as compared to untreated ovariectomized animals (p 
= 0.04) but no significant differences in double-labeled surface (dLS/BS). Raloxifene 
treatment also led to a reduction in trabecular separation compared to untreated 
ovariectomized animals (p = 0.02) (Figure 2.4). Ovariectomized animals treated with 
risedronate for three months had reduced ES/BS as compared to untreated 
ovariectomized animals (p = 0.02) (Figure 2.4). Risedronate treatment resulted in a 
reduction in double-labeled surface (dLS/BS, p < 0.01), mineralizing surface (MS/BS, 
p = 0.02) and bone formation rate (BFR/BS, p = 0.05) compared to untreated 
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ovariectomized animals (Table 2.2). Trends suggested that anti-resorptive treatment 
increased bone volume fraction as compared to ovariectomized animals but were not 
considered statistically significant (p > 0.05). 
 
Figure 2.4.Whole specimen measures of bone microarchitecture and remodeling are 
shown for each of the study groups (p < 0.05), (A) BV/TV, (B) Tb.Sp, (C), ES/BS (D) 
dLS/BS. Differences between groups analyzed using Dunn’s multiple comparisons 
test, b — p < 0.05 vs. OVX untreated. 
Three-dimensional analysis of individual resorption cavities demonstrated no 
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differences in cavity surface area (BS/Cv), maximum cavity depth (Cv.De), or cavity 
volume (Cv.V) between untreated ovariectomized animals and sham-operated 
controls. Ovariectomized animals treated with raloxifene or risedronate, however, 
showed 34.5 – 56.8% reductions in cavity surface area, maximum cavity depth and 
cavity volume as compared to untreated ovariectomized animals and sham controls (p 
< 0.01) (Table 2.1, Figure 2.5A–B). Risedronate treatment was associated with 
reductions in mean depth per cavity as compared to both untreated ovariectomized 
animals and sham controls (p < 0.01). Raloxifene treatment was associated with 
reduced mean depth per cavity as compared to sham controls (p < 0.01). No 
differences in cavity morphology were observed between animals in the OVX + Ral 
and OVX + Ris groups (Table 2.1, Figure 2.5A-B). 
Table 2.1. Static histomorphometry measures for each group are shown, mean ± SD 
across animals within a group, 95% CI (5th, 95th). 
Measurement SHAM (n=5) OVX (n=5) 
OVX+Ral 
(n=6) 
OVX+Ris 
(n=6) 
Bone volume 
fraction (BV/TV, 
%) 
31.18±6.99 
(22.50, 39.86)
20.18±4.08 
(15.12, 25.24)
25.68±5.92 
(19.47, 31.90) 
26.05±3.01 
(22.89, 29.21) 
Bone-specific 
surface (BS/BV, 
mm-1) 
9.60±1.64 
(7.53, 11.63) 
7.05±1.18 
(5.60, 8.36) 
9.03±1.20 
(7.80, 10.27) 
8.39±0.78 
(7.58, 9.18) 
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Trabecular 
thickness (Tb.Th, 
μm) 
87.52±7.57 
(78.13, 96.92)
76.14±3.20 
(72.17, 80.12)
75.13±14.58 
(59.83, 90.43) 
83.59±8.83 
(74.33, 92.85) 
Trabecular 
separation 
(Tb.Sp, μm) 
243.01±62.92 
(164.89, 
321.14) 
344.83±38.32 
(297.25, 
392.42) 
228.51±30.29 
(196.72, 
260.29)b 
268.74±41.10 
(225.61, 
311.87) 
Structural 
modeling index 
(SMI) 
1.16±0.27 
(0.82, 1.50) 
1.47±0.37 
(1.02, 1.93) 
1.48±0.34 
(1.12, 1.83) 
1.44±0.11 
(1.33, 1.56) 
Degree of 
anisotropy (DA) 
0.68±0.12 
(0.53, 0.83) 
0.65±0.08 
(0.55, 0.75) 
0.72±0.06 
(0.65, 0.79) 
0.67±0.12 
(0.54, 0.80) 
*Eroded surface 
(ES/BS, %) 
6.17±0.85 
(4.78, 7.56) 
8.52±1.11 
(7.13, 9.91) 
5.26±2.00 
(3.99, 6.52) 
5.06±1.41 
(3.79, 6.33)b 
†Median 
Maximum Cavity 
Depth (Cv.De, 
μm) 
23.66±1.87 
(21.33, 25.97)
22.88±3.69 
(18.30, 27.47)
14.96±2.30 
(12.55, 
17.38)ab 
14.94±2.70 
(12.11, 
17.77)ab 
†Median Mean 
Cavity Depth 
3.76±0.42 3.20±0.88 2.38±0.47 1.82±0.44 
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(μm) (3.23, 4.28) (2.11, 4.29) (1.89, 2.87)ab (1.36, 2.28)ab 
†Median Cavity 
Surface Area 
(BS/Cv, 103 μm2) 
17.99±2.33 
(15.11, 20.88)
19.76±3.02 
(16.01, 23.51)
9.59±2.24 
(7.24, 11.94)ab 
8.55±2.17 
(6.28, 10.82)ab 
†Median Cavity 
Volume (Cv.V, 
103 μm3) 
31.49±5.18 
(25.06, 37.92)
33.92±5.87 
(26.63, 41.21)
17.73±3.96 
(13.58, 
21.89)ab 
15.44±3.32 
(11.95, 
18.92)ab 
* - Measured in two-dimensions using line intersection. 
†-Median of 8-32 cavities within a specimen. 
a- p<0.05 vs SHAM group 
b- p<0.05 vs OVX group 
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Figure 2.5. Median measurements of individual resorption cavities and formation 
events are shown for each of the study groups (p < 0.05), (A) Cv.De, (B) Cv.V, (C), 
3D MAR (D) MS/dL.Ev. Statistical differences are shown based on generalized least 
squares regression models that include all events and donor as a random effect. a — 
p < 0.05 vs. SHAM operated, b — p < 0.05 vs. OVX untreated, and c — p < 0.05 vs. 
OVX + Ral. 
Histograms showing the distribution of sizes of cavities and formation events 
are show no difference in cavity size and formation event surface area between OVX 
and SHAM but a shift to the left in the groups treated with anti-resorptive agents 
(Figure 2.6 in Supplementary Materials). Surface area per double-labeled event 
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(MS/dL.Ev) was greater in untreated ovariectomized animals compared to all other 
groups (p < 0.01). In addition, the risedronate treated group had reduced MS/dL.Ev 
compared to both sham controls and the raloxifene treated group (p < 0.02) (Table 2.2, 
Figure 2.5D). Volume within each double-labeled formation event was reduced in 
animals treated with risedronate compared to other groups (p < 0.01) (Table 2.2). No 
differences in 3D mineral apposition rate were observed among the four groups 
(Figure 2.5C). No significant differences in the number of formation events per unit 
bone surface or in measurements of the size and number of single-labeled surfaces 
were observed between groups. As expected, median measures of formation event size 
were correlated with dLS/BS, and median measures of cavity size were correlated with 
ES/BS (See Figure 2.7 in Supplementary Materials). 
 
Table 2.2.  Dynamic bone histomorphometry measures are shown for each group, 
Mean ± SD, 95% CI (5th, 95th). 
Measurement SHAM (n=5) OVX (n=5) 
OVX+Ral 
(n=6) 
OVX+Ris 
(n=6) 
Double-labeled 
surface (dLS/BS, %) 
9.30±0.40 
(8.84, 9.82) 
12.51±4.32 
(7.15, 17.88) 
8.52±2.24 
(6.20, 10.87) 
5.16±1.83 
(3.24, 7.08)ab 
Mineralizing surface 
(MS/BS, %) 
11.44±0.76 
(10.50, 
12.39) 
13.89±4.61 
(8.17, 19.62) 
10.38±2.71 
(7.54, 13.22) 
8.14±1.98 
(6.06, 
10.22)ab 
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Single-labeled surface 
(sLS/BS, %) 
4.23±2.19 
(2.42, 6.04) 
2.75±1.11 
(0.95, 4.56) 
3.71±2.26 
(2.06, 5.36) 
5.95±1.85 
(4.30, 7.60) 
No. of double-labeled 
formation events 
(N.dL.Ev) 
59.20±33.54 
(40.64, 
77.76) 
29.40±8.68 
(10.84, 
47.96) 
38.50±16.16 
(21.55, 
55.45) 
25.17±13.56 
(8.22, 42.11) 
No. of single-labeled 
formation events 
(N.sL.Ev) 
114.00±63.52 
(77.60, 
150.40) 
49.60±18.74 
(13.20, 
86.00) 
77.50±29.15 
(44.27, 
110.73) 
110.33±32.32 
(77.11, 
143.56) 
No. of double-labeled 
formation events per 
unit bone surface 
(N.dL.Ev/BS, mm-2) 
3.20±1.32 
(2.29, 4.10) 
2.23±0.54 
(1.32, 3.14) 
2.25±0.87 
(1.43, 3.08) 
1.63±0.98 
(0.81, 2.46) 
No. of single-labeled 
formation events per 
unit bone surface 
(N.sL.Ev/BS, mm-2) 
6.50±3.61 
(4.40, 8.60) 
3.76±1.27 
(1.66, 5.87) 
2.25±0.87 
(2.71, 6.54) 
6.97±1.66 
(5.05, 8.89) 
††Median 3D mineral 
apposition rate (3D 
MAR, μm/day) 
0.71±0.13 
(0.54, 0.87) 
0.77±0.11 
(0.64, 0.90) 
0.66±0.14 
(0.52, 0.81) 
0.47±0.11 
(0.35, 0.59) 
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Bone formation rate 
(BFR/BS, μm/day) 
0.11±0.03 
(0.08, 0.15) 
0.13±0.05 
(0.10, 0.16) 
0.09±0.04 
(0.06, 0.12) 
0.05±0.05 
(0.02, 0.08) 
††Median surface 
area per double-
labeled event 
(MS/dL.Ev, 103 μm2) 
17.26±8.22 
(7.06, 27.46)b
28.53±9.89 
(16.25, 
40.80) 
18.05±4.53 
(13.29, 
22.80)b 
14.05±4.77 
(9.04, 
19.05)abc 
Median surface area 
per single-labeled 
event (MS/sL.Ev, 103 
μm2) 
3.31±2.42 
(3.01, 3.61) 
3.98±0.41 
(3.47, 4.49) 
3.74±0.64 
(3.08, 4.41) 
4.34±0.56 
(3.76, 4.93) 
††Median volume per 
double-labeled event 
(V/dL.Ev, 103 μm3) 
80.76±41.33 
(29.43, 
132.08) 
155.71±93.06 
(40.16, 
271.26) 
91.74±29.20 
(61.11, 
122.39) 
43.90±21.72 
(21.11, 
66.69)abc 
††-Median of 8-109 formation events in each specimen 
a- p<0.05 vs SHAM group 
b- p<0.05 vs OVX group 
c- p<0.05 vs OVX+Ral group 
2.5. Discussion 
Anti-resorptive agents can cause a fundamental change in the morphology of 
individual remodeling events, resulting in resorption cavities that are smaller in depth, 
volume and surface area as compared to ovariectomized animals and sham-operated 
controls. Furthermore, the anti-resorptive treatments examined here reduce the surface 
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area of individual formation events as compared to untreated ovariectomized animals. 
The reduction in resorption cavity size with anti-resorptive treatment may not be 
correlated to the reduction in the total amount of bone remodeling, because cavity size 
is reduced during raloxifene treatment as compared to sham-operated controls while 
the total amount of bone turnover (characterized by ES/BS and dLS/BS) does not 
appear to differ between the two. 
There are a number of strengths to the current study that provide confidence in 
our results. First, the current study is unique in using three-dimensional dynamic bone 
histomorphometry to examine differences in remodeling event size among treatments 
and therefore achieves the size and variability of individual events rather than 
specimen averages. Image processing and analysis using our three-dimensional 
approach has been validated thoroughly in a series of previous studies [19-21]. 
Second, the current study examined cavities that had been formed in vivo. Although 
three-dimensional studies of resorption cavity depth and breadth have been performed 
on cavities formed by osteoclasts in vitro [23-26] such measures are limited by culture 
conditions that do not exactly match the conditions in vivo. Lastly, the current study 
used older animals and began anti-resorptive treatment after allowing bone loss to be 
established, thereby simulating the effects of treatment on a pre-existing state of 
osteopenia. 
There are some limitations that must be considered when interpreting our 
results. First, we characterized the morphology of resorption cavities based on the 
observation of eroded surface and not on the presence of active osteoclasts, so our 
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results are characteristic of cancellous bone morphology but are only indirect 
measures of bone resorption. It is possible to achieve three-dimensional images of 
resorption cavities identified with tartrate resistant acid phosphatase [27], but such 
approaches are labor intensive and to our knowledge have only been applied to a 
handful of cavities. Additionally, we measured only a subset of all resorption cavities 
in each specimen. Hence, we could not directly determine if the number of resorption 
cavities was altered with treatment. In a previous study in which we traced all 
resorption cavities in each specimen, we found that established estrogen deficiency 
resulted in an increase in the number of resorption cavities but no changes in cavity 
size (depth, surface area) [19]. Although ES/BS was reduced by both anti-resorptive 
agents (p < 0.05), the current study does not allow us to make conclusions regarding 
changes in the number of resorption cavities associated with anti-resorptive treatment. 
However, we were able to examine all bone formation events within the region of 
interest. While the number of bone formation events observed varied considerably 
(range 7–82), it did not differ between the four groups after accounting for differences 
in bone surface area. 
Previous studies using two-dimensional histomorphometry approaches have 
suggested that anti-resorptive agents cause 10–30% reductions in average cavity depth 
and 20–30% reductions in cavity breadth (only two studies examined cavity breadth) 
[9-15]. In comparison, the current study found more pronounced reductions in 
resorption cavity size including a 35–51% reduction in depth and reductions in 
resorption cavity surface area of 47–57%. To the authors' knowledge, no studies have 
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measured changes in the size of bone formation events following anti-resorptive 
treatment. The current study is the first to use three-dimensional approaches to analyze 
the effects of anti-resorptive agents on the surface area and volume of individual 
resorption cavities and formation events. In comparison to previous work the current 
study does not require stereology or selection of only cavities ideal for measurement 
(which introduces selection bias [16]). 
The mechanism through which resorption cavities are reduced in size is not 
clear, but could be caused by changes in the number of osteoclasts at each resorption 
site, the amount of bone resorption by each osteoclast, the lifespan of osteoclasts at 
resorption sites or some combination of the three. Nitrogen containing 
bisphosphonates such as risedronate have been shown to reduce osteoclast 
function/lifespan, primarily by inhibiting GTPases that regulate osteoclast cytoskeletal 
rearrangement, membrane ruffling and vesicular trafficking necessary for bone 
resorption [28]. Recent work has shown that osteoclasts from mice deficient in Rac1 
and Rac2 form smaller resorption cavities in vitro [26] which is consistent with the 
idea that risedronate treatment regulates cavity size by impairing osteoclast function. 
In contrast, our finding that raloxifene also leads to reductions in cavity size as 
compared to both SHAM and OVX animals is surprising because raloxifene is 
believed to act primarily as a replacement for estrogens and was therefore expected to 
reverse any changes in bone remodeling associated with ovariectomy. Since there was 
no difference in cavity size between the SHAM and OVX groups, we expected that 
raloxifene would not alter cavity size. There are two possible explanations for the 
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changes in cavity size with raloxifene: First, it is possible that the reduction in size 
may be related to the timing of raloxifene dosage (3 times per week) leading to 
differences in the concentration of raloxifene in ovariectomized animals and 
circulating estrogens in SHAM operated animals. Second, others have noted subtle 
differences in the effects of raloxifene and estrogen on bone remodeling [29, 30] and it 
is possible that alterations in the size of individual resorption cavities may be another 
difference between raloxifene and estrogen. 
The current study is consistent with the idea that changes in resorption cavities 
may explain why reductions in fracture risk following anti-resorptive treatment are 
greater than expected from the associated changes in BMD. Reductions in maximum 
cavity depth and cavity volume associated with raloxifene and risedronate treatment 
are expected to reduce stress concentrations associated with resorption cavities, 
potentially providing benefits to bone strength independent of bone mineral density [4, 
31]. Additionally, reductions in the maximum depth of resorption cavities may also 
reduce the likelihood that a resorption cavity disconnects or fenestrates a trabecula, 
helping to preserve cancellous bone microarchitecture over time. The magnitude of 
stress concentrations associated with resorption cavities depends on the number and 
size of resorption cavities, the location of the cavity within the structure (on a 
longitudinal trabecula vs. transverse trabecula, in a highly loaded or less loaded region 
of the microstructure) and local bone morphology (local trabecular thickness, plate-
like vs. rod-like trabeculae, nodes in the structure, etc.) [4, 18]. Given the complex 
microarchitecture and load distribution within cancellous bone, additional 
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biomechanical analyses are required to understand the mechanical consequences of 
resorption cavities. 
In conclusion, our findings demonstrate that existing drug treatments have the 
ability to regulate the size of individual resorption cavities. Regulation of the size of 
individual resorption cavities may be one way in which anti-resorptive agents make 
cancellous bone more resistant to mechanical failure. Finally, regulating resorption 
cavity size has the potential to alter cancellous bone biomechanical performance in a 
way that may not be immediately apparent from measure of overall amounts of bone 
turnover. 
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2.7. Supplemental Material 
 
Figure 2.6. Histograms showing the distribution of sizes of cavities (A-C) and 
formation events (D) are shown for each of the four groups. The labels on the x-axis 
constitute discrete data bins. The distribution of cavity size and formation event 
surface area does not differ between OVX and SHAM but is shifted to the left in the 
groups treated with anti-resorptive agents.
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Figure 2.7. Scatterplot chart showing correlations between remodeling event size 
measurements and whole specimens measurements of bone remodeling are shown. 
Scatterplots were exported from JMP Pro 9 (For shaded ellipses, α = 0.95). 
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CHAPTER 3                                                      
ROMOSOZUMAB TREATMENT CONVERTS TRABECULAR RODS INTO 
TRABECULAR PLATES IN MALE CYNOMOLGUS MONKEYS 
 
The following chapter was published in Calcified Tissue International in 2017 in 
Volume 101(1), pgs. 82-91.The article is titled “Romosozumab treatment converts 
trabecular rods into trabecular plates in male cynomolgus monkeys” by Matheny JB, 
Torres AM, Ominsky MS, and Hernandez CJ and is reprinted here with permission of 
Springer. All applicable international, national, and/or institutional guidelines for the 
care and use of animals were followed. All procedures performed in studies involving 
animals were in accordance with the ethical standards of the institution or practice at 
which the studies were conducted. 
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3.1. Abstract 
Treatment with sclerostin antibody (romosozumab) increases bone formation while 
reducing bone resorption, leading to increases in bone volume and bone mineral 
density. Sclerostin antibody treatment may also provide beneficial changes in 
trabecular microarchitecture and strength that are not reflected in bone volume and 
density. Here we use three-dimensional dynamic histomorphometry to determine 
longitudinal changes in vertebral trabecular microarchitecture in adolescent male 
cynomolgus monkeys (4-5 years old) treated with sclerostin antibody. Animals were 
treated bi-weekly with either sclerostin antibody (30 mg/kg, sc, n = 6) or vehicle (n = 
6) for 10 weeks. Animals were administered fluorochrome bone formation labels on 
days 14 and 24 (tetracycline) and on days 56 and 66 (calcein), followed by necropsy 
on day 70. Cylindrical specimens of cancellous bone from the 5th lumbar vertebrae 
were used to generate high-resolution, three-dimensional images of bone and 
fluorescent labels of bone formation (0.7 × 0.7 × 5.0 µm/voxel). The three-
dimensional images of the bone formation labels were used to determine the bone 
volume formed between days 14 and 66 and the resulting alterations in trabecular 
microarchitecture within each bone. Treatment with sclerostin antibody resulted in a 
conversion of rod-like trabeculae into plate-like trabeculae at a higher rate than in 
vehicle treated animals (p = 0.01). Plate-bone volume fraction was greater in the 
sclerostin antibody group relative to vehicle (mean 43% vs. 30%, p < 0.05). Bone 
formation increased the thickness of trabeculae in all three trabecular orientations 
(axial, oblique, and transverse, p < 0.05). The volume of bone formed between days 
14 to 66 was greater in sclerostin antibody treated groups (9.0 vs. 5.4%, p = 0.02), and 
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new bone formation due to sclerostin antibody treatment was associated with 
increased apparent stiffness as determined from finite element models. Our results 
demonstrate that increased bone formation associated with sclerostin antibody 
treatment increases plate-like trabecular morphology and improves mechanical 
performance. 
3.2. Introduction 
Osteoporosis is characterized by deterioration of cancellous bone 
microstructure, including reductions in bone volume fraction and trabecular thickness 
[1]. Anabolic treatments for osteoporosis have the potential to reverse bone loss and 
recover trabecular microstructure by causing increases in new bone formation. 
Romosozumab is an antibody that blocks sclerostin, a protein secreted by osteocytes 
that negatively regulates bone formation [2-6]. Animal studies have shown that 
sclerostin antibody treatment increases modeling-based bone formation while reducing 
bone resorption [7] leading to increases in bone mass and bone strength [2, 8]. Recent 
clinical studies have shown that sclerostin antibody treatment increases bone mineral 
density in the lumbar spine and hip [9-11] and reduces vertebral fracture risk in 
postmenopausal women [12]. Although increases in bone mineral density often result 
in increases in bone strength and resistance to fracture, many osteoporosis treatments 
cause reductions in fracture risk that are greater than expected from changes in bone 
mineral density alone [13, 14]. Possible explanations for the disproportionate change 
in fracture risk include alterations in bone tissue mechanical properties, cortical-
trabecular density distribution and cancellous bone microarchitecture [15].  
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Cancellous bone microarchitecture is an aspect of bone quality that may 
influence fracture risk [15]. Traditional measures of cancellous bone microarchitecture 
include bone volume fraction, average trabecular thickness and trabecular separation 
[16]. However, direct enumeration and classification of individual trabeculae through 
Individual Trabecula Segmentation (ITS) has been shown to improve the prediction of 
cancellous bone strength and stiffness beyond what is possible with traditional 
measures [17-19]. Additionally, alterations in rod- and plate-like morphology of 
cancellous bone in patients has been associated with fragility fractures independent of 
bone mineral density determined through dual-energy X-ray absorptiometry [20]. 
Hence, changes in rod-like and plate-like trabecular microarchitecture have the 
potential to improve bone mechanical performance to a greater extent than expected 
from bone mineral density. 
While anabolic treatments clearly increase bone volume fraction, they may 
also influence aspects of cancellous microstructure that influence bone quality. The 
number and orientation of trabeculae are known to influence biomechanical 
performance of cancellous bone. It is believed that once a trabecula is resorbed during 
age-related bone loss, it cannot be reformed by subsequent bone formation and that 
subsequent increases in bone density occur through thickening of existing trabeculae 
[21]. Finite element models suggest that increasing the number of trabeculae is more 
effective at increasing cancellous bone strength and stiffness than thickening existing 
trabeculae [21]. Differentiating between increases in the number and thickness of 
trabeculae is challenging because bone formation is typically assessed in two-
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dimensional sections which do not display out-of-plane morphology, making it 
difficult to identify the presence of entirely new trabeculae [22, 23]. Three-
dimensional imaging using in vivo, serial microcomputed tomography (serial 
microCT) [24-29] or high-resolution peripheral quantitative computed tomography 
(HR-pQCT) [30-33] has been used to evaluate changes in cancellous bone 
microarchitecture due to bone formation; however, both approaches have limited 
spatial resolution (10.5 μm for serial microCT and 82 μm or higher for HR-pQCT) and 
have typically been used only to study extremities. We have demonstrated a three-
dimensional dynamic histomorphometry approach that provides assessment of bone 
formation markers in vitro [34-37], allowing for examination of changes in trabecular 
microarchitecture caused by bone formation that can be used on specimens from any 
region of the skeleton.  
While cross-sectional studies have associated sclerostin antibody treatment 
with increased bone volume fraction [2, 7, 8, 38], there are no longitudinal studies of 
alterations in trabecular microarchitecture in the spine. It is not known how treatment 
with sclerostin antibody alters the rod and plate-like morphology of individual 
trabeculae in cancellous bone. Given the anabolic nature of sclerostin antibody, we 
hypothesize that treatment will generate sufficient bone formation to increase the total 
number of trabeculae or specifically increase the number of plate-like trabeculae. The 
long term goal of the current line of investigation is to understand how changes in 
bone formation and microarchitecture influence cancellous bone biomechanics and 
fracture risk. In the current study, we combine Individual Trabecula Segmentation 
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with three-dimensional dynamic bone histomorphometry to determine the changes in 
the number and size of rod-like and plate-like trabeculae in vertebral cancellous bone 
over an 8-week period of treatment with sclerostin antibody. 
3.3. Materials and Methods 
3.3.1 Study Design 
Here we report a new analysis using tissue generated from a prior study. The 
study was performed under Institutional Animal Care and Use Committee approval at 
Charles River Laboratories (Montreal, Quebec, Canada), which has been thoroughly 
described elsewhere [7, 38]. All efforts were made to minimize animal suffering. 
Adolescent (4-5 year old) male cynomolgus monkeys (Macaca fascicularis) were used 
in the study because the monoclonal antibody (romosozumab) can only be used 
effectively in humans or primates. The animals were cared for in accordance to the 
Guide for the Care and Use of Laboratory Animals, and were maintained in 
Association for Assessment and Accreditation of Laboratory Animal Care 
International – accredited facilities in species-specific housing on a 12:12 hour light: 
dark cycle. The animals were socially housed indoors in environmental conditions 
24°C ± 3°C, 50% ± 20% humidity, and were allowed normal physical activity. 
Animals were fed twice daily a certified pelleted primate diet (2050C Certified Global 
20% Protein Primate Diet: Harlan Teklad) in amounts appropriate for the age and size 
of the animals. In addition, each animal was offered food supplements daily in any 
combination of the following: Golden Banana Softy®, Prima-Treat® (5 g format), 
fresh or dried fruit, fresh or dried vegetables and at least once weekly Prima-Foraging 
Crumbles® (20-25 g) as part of the environmental enrichment program. Animals had 
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ad libitum access to water that was treated by reverse osmosis and ultraviolet 
radiation. 
The cynomolgus monkeys were randomly assigned to receive either sclerostin 
antibody (Scl-Ab, 30 mg/kg romosozumab, subcutaneous injection, n = 6) or vehicle 
(10 mM sodium acetate, 9% sucrose, 0.004% polysorbate 20, pH 5.2, n = 6) biweekly 
for 10 weeks. Animals received fluorochrome labels on days 14 and 24 (25 mg/kg 
tetracycline, intravenous) and on days 56 and 66 (8 mg/kg calcein, intravenous) 
following treatment. Romosozumab was well tolerated by the animals, and no adverse 
effects of sclerostin inhibition were observed. Following administration of a sedative 
(ketamine, intramuscular injection), monkeys were euthanized by intravenous 
injection of sodium pentobarbital followed by exsanguination by incision of the 
axillary or femoral arteries (see Figure 3.1). The fifth lumbar vertebra was stored at -
20 °C. 
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Figure 3.1. The timing of treatment and fluorochrome labeling in the study design are 
illustrated. Male cynomolgus monkeys were administered either sclerostin antibody 
(Scl-Ab, n = 6) or vehicle. Animals received fluorochrome labels on days 14 and 24 
(tetracycline) and on days 56 and 66 (calcein) following treatment, and were 
euthanized at day 70. 
3.3.2 Image Acquisition and Processing 
Cylindrical specimens of cancellous bone (4 mm in height, 5 mm diameter) 
were obtained from the center of the 5th lumbar vertebral body. Bone marrow was 
removed from the specimens using a low pressure water jet and specimens were 
embedded undecalcified in methyl-methacrylate. Three-dimensional images of bone 
and fluorochrome labels were obtained using serial milling (voxel size of 0.7 × 0.7 × 
5.0 μm) as described previously (See Figure 3.2) [34-36]. Serial milling uses a 
custom-made system that involves repeatedly removing the top 5 μm from the 
specimen using a computer controlled milling system (Benchman MX, Intelitek, 
Manchester, NH, USA) and collecting a mosaic of images from the newly revealed 
block face using epifluorescence microscopy. Three fluorescent images were collected 
of each cross-section using different filter sets: one for bone autofluorescence 
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(390/460 nm Ex/Em), one for tetracycline labels (390/630 nm) and one for calcein 
labels (480/535 nm). A manually determined global threshold was selected by a 
trained observer to segment bone and fluorescent labels (tetracycline and calcein). The 
segmentation approach has been shown to provide similar results as two-dimensional 
histomorphometry measurements with low inter-observer variation [34]. A cylindrical 
region of interest of 2 mm in height, 4 mm in diameter from the center of each 
specimen was used for analysis. 
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Figure 3.2. (A) A representative cross-section from a cancellous bone specimen with 
bone and fluorescent formation markers (tetracycline yellow (B) and calcein green 
(C)) obtained using serial milling at a voxel size of 0.7 × 0.7 × 5.0 μm. The two pairs 
of bone formation labels were merged using three-dimensional morphological closing 
to isolate the Formation Volume (D).Three-dimensional images of bone and bone 
formation were created from the collection of two-dimensional cross-sections 
(Formation Volume shown in green) (E-F).  
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3.3.3 Three-dimensional Measurements of Bone Formation 
Three-dimensional dynamic bone histomorphometry differs from traditional 
dynamic histomorphometry in that it measures bone formation throughout the 
specimen and is therefore not subject to limitations associated with stereology or 
“label escape error,” making it possible to evaluate changes in bone formation in a 
region of cancellous bone and longitudinal assessment of changes in bone 
microstructure caused by bone formation. Three-dimensional measures of bone 
formation were generated from the images using measurement approaches described 
previously [34]. Three-dimensional mineral apposition rate (3D MAR) and 
mineralizing surface (3D MS/BS) were determined for each of the two pairs of 
fluorescent labels (one pair of tetracycline and one pair of calcein) [34]. Three-
dimensional bone formation rate was calculated as the mineral apposition rate 
multiplied by the mineralizing surface (3D BFR/BS-Tet and 3D BFR/BS-Cal). In 
addition to determining the bone formation indices of each of the two pairs of 
fluorescent labels, the entire volume of bone formed between the administration of the 
first tetracycline label (day 14), the last calcein label (day 66) and the bone formed 
between the last calcein label and euthanasia (day 70) was determined by merging all 
of the fluorescent labels and the adjacent surface in the three-dimensional image using 
morphological closing. The resulting volume was referred to as the Formation Volume 
(FV) and represents a direct measure of the entire volume of bone formed during the 8 
week period between first and last formation labels (Figure 3.2). The changes in 
trabecular microarchitecture between images with and without the Formation Volume 
therefore approximated longitudinal changes in trabecular morphology. 
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3.3.4 Individual Trabecula Segmentation Based Analyses 
The morphology of individual trabeculae was analyzed using Individual 
Trabecula Segmentation (ITS, Columbia University). Images were coarsened to 21 × 
21 × 21 μm voxels to reduce computational time and to provide measures consistent 
with prior work [17]. Individual Trabecula Segmentation associates each voxel of 
bone in the image with a discrete trabecula and then characterizes the trabecular 
morphology (rod-like, plate-like) and orientation (axial, oblique, and transverse, See 
Figure 3.3) (Please see [17] for further details). The plate-bone volume fraction 
(pBV/TV) and rod-bone volume fraction (rBV/TV) were measured for each group 
along with measurements of volume fraction and trabecular thickness for each 
trabecular orientation (axial, oblique and transverse). To determine the longitudinal 
changes in rod-like and plate-like morphology and trabecular orientation caused by 
bone formation during the experiment, ITS was performed on the final images as well 
as the same images after removal of the Formation Volume. The number of trabeculae 
that were changed from rod-like to plate-like as a result of bone formation during the 8 
week period of the experiment was then determined. Extensive analysis for entirely 
new trabeculae formed between the first and last formation labels was performed. 
Traditional three-dimensional measurements of bone (bone volume fraction (BV/TV), 
trabecular thickness (Tb.Th.), trabecular separation (Tb.Sp.), and structure model 
index (SMI) were measured using BoneJ [39].  
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Figure 3.3. Three-dimensional images of bone formation and local trabecular 
morphology and orientation are shown for each group. Cancellous bone specimens 
from the 5th lumbar vertebra for each group are shown for (A) bone formation volume 
(B) plate-like and rod-like trabecular microstructure and (C) trabecular orientation for 
each group. 
3.3.5 Serum Markers of Bone Formation 
Serum osteocalcin (OC) and intact N-terminal propeptide of type 1 procollagen 
(P1NP), markers of bone formation, were measured using radioimmunoassay (OC: 
DSL-6900, Diagnostic System Laboratories country; P1NP: Intact P1NP, Orion 
Diagnostica) at various time points, with the day 14 time point corresponding to the 
initial fluorochrome label utilized for regression analysis. Please see Ominsky et al. 
for a full description of experimental procedures [8, 38] . 
3.3.6 Finite Element Analysis 
Linear elastic finite element models were created from three-dimensional images of 
the cancellous bone specimens (21-μm voxels) with and without the bone formed 
during the 8 weeks between formation labels. Each finite element model consisted of 
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0.62 - 1.69 million elements. Bone tissue was assumed to be an isotropic, linear elastic 
material with Young’s modulus 10 GPa and Poisson’s ratio of 0.3. To determine axial 
stiffness, an apparent compressive strain of 1% was applied to the top surface in the 
axial direction (z-axis), and vertical displacement on the opposite surface was fixed. 
To determine transverse stiffness, a cubic region of interest 2 mm in size was taken 
from the center of each specimen and finite element models were created with 
displacement applied in the transverse direction (y-axis). Apparent stress was 
calculated from the sum of the reaction forces on the constrained surface divided by 
the cross-sectional area of the surface. Apparent stiffness was calculated as the 
apparent stress divided by the applied apparent strain. Finite element models were 
implemented using Abaqus (Abaqus 6.9, Dassault Systèmes, Velizy-Villacoublay, 
France) with the Abaqus/Standard solver. 
3.3.7 Statistical Analysis 
Differences in three-dimensional measurements of bone formation, bone 
microarchitecture and ITS-based measurements between vehicle and sclerostin 
antibody treated groups were identified using two-tailed t-tests with JMP (JMP Pro 
10.0.2, SAS Institute Inc., Cary, NC, USA). In addition, linear regression analyses 
were performed with JMP. A p-value of 0.05 was used to determine statistical 
significance. 
3.4. Results 
Over the 8 week period of the study, more rod-like trabeculae were converted 
to plate-like trabeculae in animals treated with sclerostin antibody (10.27 ± 3.59%, 
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mean ± SD) than in vehicle treated animals (4.45 ± 3.48%, p = 0.017, see Figure 3.4, 
Table 3.1). The volume of bone formed over the 8 week study period (Formation 
Volume) was 68% greater in sclerostin antibody treated animals as compared to 
vehicle controls (p = 0.015, See Figure 3.5A, Table 3.2). The increase in newly 
formed bone volume was achieved by an increase in bone formation rate (3D BFR/BS, 
p = 0.001) (See Figure 3.5B, Table 3.2). The increases in 3D MAR, 3D MS/BS and 
3D BFR/BS due to sclerostin antibody treatment early in the study (days 14-24 
observed with tetracycline) was similar to that later in the study (days 56-66, observed 
with calcein, Table 3.2). Additionally, serum markers of bone formation (OC and 
P1NP) measured two weeks following treatment were strongly correlated with the 
three-dimensional bone formation rate (see Figure 3.5C-D). Extensive examination of 
the specimens failed to provide evidence of the formation of entirely new trabeculae.  
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Figure 3.4. Sclerostin Antibody converts trabecular rods to trabecular plates. (A) An 
example of the conversion of rod-like trabeculae to a plate-like trabecula is shown 
(sclerostin antibody treated animal). (B) The percentage of rod-like trabeculae which 
were converted to plate-like trabeculae during the 8-week study period is shown. 
 
Table 3.1. Traditional and ITS-based bone microstructural measurements are shown 
for each group, Mean ± SD, 95% CI (5th, 95th).  
Measurement Vehicle (n = 6) Scl-Ab (n = 6) 
p-
value 
Bone Volume Fraction 
(BV/TV, %) 
42.10 ± 12.14 
(29.37, 54.84) 
53.87 ± 4.68 
(48.96, 58.78) 
0.051 
Trabecular thickness 
(Tb.Th, µm) 
219.18 ± 42.35 
(174.74, 263.63) 
272.39 ± 
33.66 
(237.06, 
0.037 
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307.71) 
Structural modeling Index 
(SMI) 
0.99 ± 0.82 
(0.13, 1.85) 
0.13 ± 0.47 
(-0.36, 0.62) 
0.050 
Trabecular Separation       
(Tb.Sp, µm) 
679.97 ± 32.94 
(645.40, 714.54) 
687.12 ± 
29.95 
(655.69, 
718.55) 
0.702 
Plate-Bone Volume Fraction 
(pBV/TV, %) 
30.08 ± 12.90 
(16.55, 43.61) 
42.88 ± 4.67 
(37.98, 47.78) 
0.045 
Rod-Bone Volume Fraction 
(rBV/TV, %) 
12.31 ± 3.38 
(8.76, 15.86) 
11.41± 3.30 
(7.94, 14.88) 
0.650 
Plate Volume/Bone Volume 
(pBV/BV, %) 
69.00± 12.55 
(56.45, 81.55) 
79.63 ± 5.97 
(73.65, 85.60) 
0.091 
Plate Bone Volume /Rod Bone 
Volume (pBV/rBV) 
2.66 ± 1.53 
(1.06, 4.27) 
4.06 ± 1.33 
(2.67, 5.46) 
0.121 
Plate-like Trabecular Thickness 
(pTb.Th, µm) 
194.15 ± 36.90 
(155.43, 232.87) 
239.33 ± 
27.29 
(210.70, 
267.96) 
0.037 
Rod-like Trabecular Thickness 
(rTb.Th, µm) 
153.92 ± 7.74 
(145.79, 162.05) 
166.66 ± 8.99 
(157.23, 
176.09) 
0.025 
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No. of rods converted to plates / No. 
rods (%) 
4.45 ± 3.48 
(0.80, 8.10) 
10.27 ± 3.59 
(6.50, 14.05) 
0.017 
Axial-Bone Volume Fraction 
(aBV/TV, %) 
19.12 ± 6.24 
(12.62, 25.72) 
26.32 ± 2.66 
(23.54, 29.12) 
0.026 
Oblique-Bone Volume Fraction 
(oBV/TV, %) 
11.97 ± 3.46 
(8.33, 15.60) 
15.13 ± 2.20 
(12.82, 17.45) 
0.088 
Transverse-Bone Volume Fraction 
(tBV/TV, %) 
11.34 ± 3.23 
(7.95, 14.73) 
12.87 ± 2.75 
(9.99, 15.76) 
0.396 
Axial-Trabecular Thickness 
(aTb.Th, µm) 
225.02 ± 41.27 
(181.71, 268.32) 
273.62 ± 
32.71 
(239.30, 
307.94) 
0.047 
Oblique-Trabecular Thickness 
(oTb.Th, µm) 
229.04 ± 46.20 
(180.55, 277.52) 
285.26 ± 
37.18 
(246.23, 
324.28) 
0.043 
Transverse-Trabecular Thickness 
(tTb.Th, µm) 
224.70 ± 42.00 
(180.62, 268.77) 
283.83 ± 
36.17 
(245.87, 
321.78) 
0.026 
Axial Apparent Stiffness 
(MPa) 
2270 ± 1113 
(1102, 3438) 
3327 ± 416 
(2891, 3764) 
0.054 
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Transverse Apparent Stiffness (MPa)
1464 ± 852 
(570, 2358) 
2401 ± 439 
(1940, 2862) 
0.038 
 
 
Figure 3.5. Sclerostin Antibody increases three-dimensional bone formation related to 
serum markers of bone formation. Three-dimensional measurements of bone 
formation are shown for each group (A) Newly formed bone volume, (B) Bone 
formation rate. Percentage change in (C) serum osteocalcin (OC) and (D) and serum 
intact N-terminal propeptide of type 1 procollagen (P1NP) as measured two weeks 
following treatment and compared to baseline levels (week 0) correspond to the three-
dimensional bone formation rate. 
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Table 3.2 Three-dimensional dynamic bone histomorphometry measurements are 
shown for each group, Mean ± SD, 95% CI (5th, 95th).  
Measurement Vehicle (n = 6) 
Scl-Ab (n = 
6) 
p-
value 
Newly formed volume fraction 
(FV/TV, %) 
5.38 ± 2.04 
(3.24, 7.53) 
9.04 ± 2.28 
(6.65, 11.44) 
0.015 
3D Mineralizing Surface 
(3D MS/BS, %) 
26.30 ± 8.80 
(17.07, 35.53) 
40.35 ± 5.07 
(35.03, 
45.67) 
0.007 
3D Mineral Apposition Rate 
(3D MAR, µm/day) 
0.69 ± 0.05 
(0.63, 0.74) 
0.84 ± 0.05 
(0.79, 0.89) 
0.0003 
3D Bone Formation Rate 
(3D BFR/BS, µm/day) 
0.18 ± 0.07 
(0.11, 0.25) 
0.34 ± 0.05 
(0.29, 0.39) 
0.001 
3D Mineralizing Surface- 
Tetracycline Labels 
(3D MS/BS-Tet, %) 
14.10 ± 10.82 
(2.74, 25.46) 
33.32 ± 9.77 
(23.07, 
43.58) 
0.009 
3D Mineral Apposition Rate- 
Tetracycline Labels 
(3D MAR-Tet, µm/day) 
1.45± 0.19 
(1.25, 1.65) 
1.55 ± 0.07 
(1.48, 1.63) 
0.260 
3D Bone Formation Rate- 
Tetracycline Labels 
(3D BFR/BS-Tet, µm/day) 
0.22 ± 0.19 
(0.02, 0.42) 
0.52 ± 0.17 
(0.34, 0.70) 
0.016 
3D Mineralizing Surface- Calcein 12.32 ± 7.49 34.40 ± 9.29 0.001 
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Labels 
(3D MS/BS-Cal, %) 
(4.46, 20.19) (24.65, 
44.15) 
3D Mineral Apposition Rate- 
Calcein Labels 
(3D MAR-Cal, µm/day) 
1.42 ± 0.18 
(1.23, 1.60) 
1.63 ± 0.12 
(1.50, 1.75) 
0.038 
3D Bone Formation Rate- 
Calcein Labels 
(3D BFR/BS-Cal, µm/day) 
0.17 ± 0.10 
(0.07, 0.27) 
0.56 ± 0.16 
(0.39, 0.72) 
0.0004 
Sclerostin antibody treatment was associated with large changes in trabecular 
rod- and plate-like morphology, including increases in the plate-bone volume fraction 
(p < 0.045, See Figure 3.6A, Table 3.1). Additionally, sclerostin antibody treatment 
increased the thickness of both plate-like and rod-like trabeculae compared to controls 
(p < 0.05, Table 3.1). Increases in trabecular thickness associated with sclerostin 
treatment were distributed uniformly among trabeculae with different orientation 
(axial, oblique and transverse) (p < 0.05, See Figure 3.6D, Table 3.1). Additional ITS-
based microstructural measurements can be found in Table 3.3 in Supplementary 
Materials. 
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Figure 3.6. Sclerostin antibody treatment improves trabecular morphology and 
orientation. (A) Whole specimen measurements of Plate-bone volume fraction are 
shown for each group. (B) Trabecular thickness was increased in all trabecular 
orientations due to sclerostin antibody treatment (p<0.05 vs Veh for each orientation). 
Sclerostin antibody treatment increased apparent stiffness in the axial and 
transverse directions compared to vehicle controls (p = 0.038-0.054, Table 3.1). 
Apparent stiffness in both directions was strongly correlated with measurements of 
cancellous bone microarchitecture such as bone volume fraction, plate-bone volume 
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fraction, and axial-bone volume fraction (See Figure 3.7 in Supplementary Materials).  
3.5. Discussion 
Over an 8 week period, treatment with sclerostin antibody increased bone 
formation leading to a conversion of rod-like trabeculae to plate-like trabeculae and an 
increase in thickness of trabecular plates and rods in cancellous bone. Trabecular 
orientation did not influence where sclerostin antibody-induced bone formation 
occurred. Bone volume fraction correlated strongly with mechanical performance in 
our high resolution finite element models, regardless of treatment condition. No 
measurements of local trabecular morphology or orientation imparted any additional 
improvements to prediction of cancellous bone mechanical performance beyond what 
could be attributed to bone volume fraction.  
We did not observe the formation of entirely newly trabeculae in any of the 
specimens. Banse and colleagues observed new trabecular connections, or “bridges” in 
two-dimensional, backscatter electron microscopy images. Banse surmised that these 
bridges were repairing struts perforated by osteoclastic resorption [22, 23]. In 
analyzing trabecular bone in three-dimensions, we observed multiple cross-sectional 
images of trabecular bridges that were not, in fact newly formed trabeculae. That no 
newly formed trabeculae were observed in cancellous bone with enhanced bone 
formation supports the idea that fenestration and loss of trabeculae during remodeling 
is irreversible [21]. 
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The current study was able to analyze the rod-like and plate-like structure of 
individual trabeculae, providing the most detailed description of changes in trabecular 
morphology associated with treatment to date. The ITS analysis is more representative 
of trabecular microstructure than traditional measures such as structure model index 
(SMI), which measures rod and plate-like trabecular morphology based solely on strut 
curvature. Salmon and colleagues argue that the SMI measurement is confounded by a 
strong correlation with bone volume fraction and, consequently, does not in fact 
measure the rod-and plate-like structure of trabecular bone [40]. Our findings are 
consistent with a report by Maquer and colleagues in which bone volume fraction and 
fabric anisotropy explained mechanical stiffness of cancellous bone and that 
morphological measurements from either individual trabecula segmentation or 
trabecular bone score (TBS) provided no improvement in predicting cancellous bone 
stiffness [41]. 
The current study demonstrates a new method of analyzing longitudinal 
changes in trabecular microarchitecture associated with bone formation. Longitudinal 
evaluation of changes in trabecular microarchitecture has been performed with 
repeated, or “serial”, microcomputed tomography applied to live animals [24-29]. 
Altman and colleagues showed that bone formation due to combined parathyroid 
hormone and alendronate treatment increased plate-like trabecular microarchitecture 
in rats over 12 days of treatment [24]. Lambers and colleagues used serial 
microcomputed tomography to observe changes in bone formation and resorption due 
to cyclic mechanical loading in a mouse-tail loading model [29]. Christen and 
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colleagues have correlated bone formation and resorption measured using HR-pQCT 
with locations of physiological tissue loading in the human distal tibia. While serial 
microcomputed tomography and HR-pQCT are non-invasive and non-destructive 
methods to access remodeling sites in cancellous bone, both approaches are subject to 
limitations. In vivo, serial microCT approaches are unable to accurately capture small 
bone formation events due to voxel size (10-11 μm) and are limited to the extremities 
of small animal species. HR-pQCT allows for the imaging of human bone tissue but is 
even more limited to in capturing bone formation due to a voxel size (often 82 μm or 
greater). In contrast, longitudinal imaging of bone formation using serial milling, 
while time intensive, can be performed on a specimen from any skeletal site and has a 
voxel size of 1-5 μm allowing for the detection of small or newly initiated locations of 
bone formation. Additionally, serial milling involves visualization of bone formation 
using fluorochrome labels (the gold standard for assessment of bone formation) 
making it more sensitive to bone formation in cancellous bone than in vivo microCT 
or HR-pQCT, which may present errors due to partial volume effects at bone surfaces 
[28]. We confirmed the validity of our three-dimensional measurements by comparing 
them to whole system markers for bone formation. Serum markers for bone formation 
(OC and P1NP) were strongly correlated with the three-dimensional dynamic bone 
histomorphometry (r2 = 0.65 for both, Figure 3.5C-D). Correlations between three-
dimensional measurements of bone formation and serum markers are similar, and in 
some cases stronger, to correlations between two-dimensional images of fluorochrome 
labels and serum markers of bone formation [8, 42].  
  
110 
 
An important limitation of the current study is that we do not account for 
resorption that occurred during the 8-week period, resulting in slight changes to the 
initial trabecular microstructure. We expect that not accounting for resorption volume 
may explain why the percentage of rods converted to plates in vehicle controls was 
greater than zero, which would be expected following balanced bone remodeling. 
Sclerostin antibody treatment increases modeling-based formation (bone formation not 
preceded by bone resorption) and reduces bone resorption [7] so any effects of 
resorption would be minimal. A previous study using these animals has shown that 
alterations in bone formation and resorption due to sclerostin antibody treatment did 
not change bone matrix quality in comparison to vehicle controls [43]. An additional 
limitation of the current study is that our analysis was limited to the 5th lumbar 
vertebra. Although we did not examine other regions of the skeleton, a previous study 
found that treatment with sclerostin antibody increased bone formation (bone 
formation rate) as well as trabecular microstructure (trabecular thickness) in both the 
proximal tibia and 2nd lumbar vertebra in adolescent female cynomolgus monkeys 
[8], suggesting that our findings may be indicative of changes elsewhere in the 
skeleton. 
In conclusion, sclerostin antibody improved the trabecular morphology of 
cancellous bone by a prolonged increase in bone formation over 8 weeks. 
Improvements in local trabecular morphology due to sclerostin antibody may 
counteract the reduction in plate-like bone volume associated with osteoporosis.  
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3.7. Supplemental Materials 
Table 3.3. Additional ITS-based bone microstructural measurements are shown for 
each group, Mean ± SD, 95% CI (5th, 95th).   
Measurement Vehicle (n = 6) Scl-Ab (n = 6) p-
value 
Volume of rods converted to plates / 
Volume of rods (%) 
2.37± 1.84 
(0.43, 4.30) 
6.20 ± 2.45 
(3.63, 8.77) 
0.012 
No. of plate-like trabeculae (pTb.N) 809.00± 190.78  
(608.79, 1009.20) 
933.83± 
178.44 
 (746.57, 
0.269 
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1121.10) 
No. of rod-like trabeculae 
 (rTb.N) 
499.00± 150.26  
(341.32, 656.68) 
404.67± 
143.53  
(254.04, 
555.29) 
0.292 
No. of plate-like trabeculae/ No. of 
rod-like trabeculae 
1.75 ± 0.69  
(1.03, 2.48) 
2.41 ± 0.42 
 (1.98, 2.85) 
0.072 
Plate-Plate Junction Density 
 (P-P Junc.D, 1/mm3) 
24.71 ± 5.36 
(19.08, 30.24) 
26.83 ± 7.23 
(19.25, 34.41) 
0.577 
Plate-Rod Junction Density 
 (P-R Junc.D, 1/mm3) 
28.65 ± 6.04 
(22.31, 34.99) 
27.41 ± 8.40 
(18.60, 36.23) 
0.776 
Rod-Rod Junction Density  
(R-R Junc.D, 1/mm3) 
5.53± 2.78 
(2.61, 8.45) 
3.56 ± 1.63 
(1.84, 5.27) 
0.165 
Axial Volume/Bone Volume 
(aBV/BV, %) 
44.82 ± 3.86 
(40.96, 48.67) 
48.66 ± 5.67 
(42.99, 54.34) 
0.200 
Oblique Volume/Bone Volume 
(oBV/BV, %) 
28.23 ± 2.38 27.77 ± 1.97 0.722 
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(25.85, 30.60) (25.80, 29.74) 
Transverse Volume/Bone Volume 
(tBV/BV, %) 
26.97 ± 3.00 
(23.97, 29.97) 
23.58 ± 4.09 
(19.49, 27.67) 
0.133 
 
  
Figure 3.7. Correlation Scatterplots for measurements of stiffness derived from high 
resolution finite element models and traditional and ITS-based measurements of bone 
microstructure are shown.  
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CHAPTER 4                                                          
MATERIAL HETEROGENEITY IN CANCELLOUS BONE PROMOTES DEFORMATION 
RECOVERY AFTER MECHANICAL FAILURE 
 
The following chapter was published in the Proceedings of the National Academy of Sciences 
(PNAS) in 2016 in Volume 113(11), pgs. 2892-2897. The article is titled “Material heterogeneity 
in cancellous bone promotes deformation recovery after mechanical failure” by Torres AM, 
Matheny JB, Keaveny TM, Taylor D, Rimnac CM, and Hernandez CJ and is reprinted here with 
permission of PNAS. One paragraph discussing resorption cavities, which was not included in 
the PNAS article has been added to the introduction. Authors Torres AM, and Matheny JB 
contributed equally to the published work. Torres contributed primarily to the mechanical testing 
and serial milling imaging of cancellous bone specimens and analysis of advanced glycation end 
products. Matheny contributed primary to the analyses involving microscopic tissue damage, 
resorption cavities and mechanical stresses from finite element analysis.  
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4.1. Abstract 
Many natural structures use a foam core and solid outer shell to achieve high strength and 
stiffness with relatively small amounts of mass. Biological foams, however, must also resist 
crack growth. The process of crack propagation within the struts of a foam is not well understood 
and is complicated by the foam microstructure. We demonstrate that in cancellous bone, the 
foam-like component of whole bones, damage propagation during cyclic loading is dictated not 
by local tissue stresses but by heterogeneity of material properties associated with increased 
ductility of strut surfaces. The increase in surface ductility is unexpected because it is the 
opposite pattern generated by surface treatments to increase fatigue life in man-made materials, 
which often result in reduced surface ductility. We show that the more ductile surfaces of 
cancellous bone are a result of reduced accumulation of advanced glycation end products as 
compared to the strut interior. Damage is therefore likely to accumulate in strut centers making 
cancellous bone more tolerant of stress concentrations at strut surfaces. Hence the structure is 
able to recover more deformation after failure, and return to a closer approximation of its original 
shape. Increased recovery of deformation is a passive mechanism seen in biology for “setting” a 
broken bone that allows for a better approximation of initial shape during healing processes, and 
is likely the most important mechanical function. Our findings suggest a novel biomimetic 
design strategy in which tissue level material heterogeneity in foams can be used to improve 
deformation recovery after failure.  
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4.2. Significance Statement  
 Lightweight structures often employ foam cores to achieve high strength and stiffness. 
Structures that are submitted to cyclic loading with long service lives must also resist crack 
propagation. We show that the foam-like regions of cancellous bone resist damage propagation 
by varying material heterogeneity within struts, a strategy that makes the material less 
susceptible to stress concentrations at the surface and enhances the ability of the structure to 
recover its initial shape after mechanical failure. The ability to recover deformation after failure 
improves long-term function of bones after a fracture. Our findings suggest a novel design 
strategy of man-made foams in which material heterogeneity can be used to mitigate the effect of 
local failure to better maintain mechanical function. 
4.3. Introduction 
Many natural structures achieve a combination of low weight and mechanical properties 
that surpass what is currently possible with man-made materials [1]. A common structural motif 
in biological materials is a foam-like structure encased within a thin shell, a structure that uses 
less mass to achieve the same resistance to bending and torsional loads of solid structures [2, 3]. 
Foam core structures are seen in many biological systems including plants, feather stems and 
bones [2, 4]. In addition to increasing resistance to bending and torsional loads, the foam cores in 
biological materials must also resist failure from cracks and other damage generated by cyclic 
loading. However, little is known about the contribution of material toughness to failure in foams 
and other cellular solids.  
Whole bones consist of a dense shell of cortical bone surrounding a foam-like tissue 
called cancellous bone. Bone tissue itself is a hierarchical composite consisting of a mineral 
component (primarily impure hydroxyapatite) and an organic polymer component (primarily 
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type I collagen). In bone, tissue level material toughness has been identified as a key mechanism 
in resisting osteoporosis- and age-related fractures [5]. The ability of bone tissue to resist crack 
growth has been studied predominately in cortical bone and is a result of a combination of 
intrinsic (ahead of crack tip) and extrinsic (behind crack tip) toughening mechanisms [6-9] 
resulting in a fracture toughness, KIC, ranging from 2-8 MPa m1/2 [6, 10, 11]. Advanced glycation 
end products accumulate in bone tissue over time and have been shown to have a detrimental 
effect on resistance to crack growth and fracture [12-14]. The most influential extrinsic 
toughening features in cortical bone are associated with a self-healing process called bone 
remodeling. During bone remodeling, discrete locations of old or damaged tissue are removed 
and replaced with newly synthesized material [15]. Completed remodeling sites have highly 
mineralized boundaries known as cement lines that contribute to crack deflection, thereby 
increasing tissue toughness [9, 16].  
In engineering structures, stress risers are a common location for the initiation and 
propagation of microscopic tissue damage [17-19]. In bone there are many naturally occurring 
stress risers including resorption cavities formed during bone remodeling.  Resorption cavities 
increase local stresses and strains [19, 20] and theoretical models predict that resorption cavities 
have a disproportionate effect on bone stiffness and strength of cancellous bone [21-23]. The 
mechanical effect of a stress riser is related to its size and local geometry [24]. Resorption 
cavities with a larger depth relative to local trabecular thickness can result in larger gross stress 
concentration and therefore more likely to promote microdamage [18, 25, 26].   
The great majority of osteoporosis-related fractures occur in regions of the skeleton 
dominated by cancellous bone, yet little is known about resistance to crack growth in cancellous 
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bone tissue. Cancellous bone has a complex anisotropic microstructure made up of a network of 
struts called trabeculae (typically 400 μm long and 120 μm thick). Fracture toughness associated 
with flaws much larger than individual trabeculae (crack length 1 mm or larger) has been shown 
to be related to overall porosity in cancellous bone [4, 27, 28]. Tissue level toughness also 
influences failure of cancellous bone, but resistance to crack growth within individual trabeculae 
has not been reported previously and it is therefore unclear if alterations in tissue level material 
toughness contribute to osteoporosis- and age-related fractures in regions of cancellous bone.  
Here we examine the propagation of tissue damage in cancellous bone during fatigue 
loading using a novel three-dimensional imaging approach known as serial milling. We report 
the propagation of 1,676 locations of tissue damage and the effects of local tissue stresses and 
stress concentrations on the surface of trabeculae. We find the propagation of tissue damage to 
be insensitive to local stresses and instead appear to be dominated by heterogeneities in tissue 
material properties related to accumulation of advanced glycation end products. We conclude 
that tissue level material heterogeneity in cancellous bone enhances deformation recovery of the 
structure, which promotes recovery of function after injury. 
4.4. Materials and Methods 
4.4.1 Specimen Collection 
The fourth lumbar vertebral bodies of 11 human donors (4 male, 7 female, aged 62-88 
years, tissue source NDRI) were examined in this study. Cylindrical cores of cancellous bone 
aligned in the superior-inferior direction (nominally 8 mm in diameter and 27 mm in length) 
were dissected from each vertebral body. Specimens were wrapped in saline soaked gauze and 
stored in airtight tubes at -20 °C prior to mechanical testing. Bone marrow was removed with a 
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low-pressure water jet. Each specimen was press fit into cylindrical brass end-caps and secured 
with cyanoacrylate glue (Loctite 401, Newington, CT, USA). Specimens were stored overnight 
at 4 °C while hydrated with saline soaked gauze to allow the glue to cure. 
4.4.2. Mechanical Testing 
Specimens were submitted to cyclic compressive loading in two separate cyclic bouts. 
Mechanical testing was performed at room temperature (23 °C). To maintain hydration during 
fatigue testing, specimens were kept hydrated with physiologically buffered saline (pH of 7.4). 
Strain was measured with a 25 mm gage length extensometer (MTS, Eden Prairie, MN, USA) 
attached to the specimen’s end-caps. Applied load was measured with a load cell (100lb capacity, 
SSM-100, Transducer Techniques, CA, USA). Prior to each bout of loading, ten preconditioning 
cycles between 0 and 0.1% strain at a rate of 0.5 % per second were applied. Fatigue loading was 
applied cyclically between 0 N and a compressive load corresponding to σ = E0* 0.0035 mm/mm 
at a 4 Hz haversine waveform, where σ is stress and E0 is the initial Young’s modulus of the 
specimen (determined during preconditioning cycles, Figure 4.12A in Supplementary Materials. 
The first bout of fatigue loading was stopped prior to overt failure by detecting rapid changes in 
the creep-fatigue curve (Figure 4.1B). Following the first bout of cyclic loading, specimens with 
end-caps were carefully removed and bulk stained in xylenol orange solution (0.5 mM, Sigma 
Chemical Co., St. Louis, MO). Specimens remained fully immersed in xylenol orange for 2 
hours to label damage zones generated from the first bout of loading [29]. The specimens were 
then rinsed in three 20-minute washes of deionized water. The specimens were returned to the 
testing device, and a second bout of fatigue loading was applied until 5% apparent strain (Figure 
4.1B). A negligible reduction in Young’s modulus was caused by interruption of loading (Figure 
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4.12B in Supplementary Materials). Following the second bout of loading, specimens were 
carefully removed from the testing device and bulk stained in calcein solution (0.5 mM, Sigma 
Chemical Co., St. Louis, MO) to label damage zones generated during the second bout of 
loading using the same 2 hour incubation period and rinses as the first damage stain [29]. 
Specimens were then removed from the end-caps using a low-speed diamond saw (Isomet, 
Buehler Ltd., Lake Bluff, IL) and embedded in methyl-methacrylate made opaque with sudan 
black dye in preparation for image acquisition using serial milling [30].  
4.4.3. Microscopic Tissue Damage  
Three-dimensional images of bone and fluorescent markers of damage zones were 
collected using serial milling to achieve a voxel size of 0.7 x 0.7 x 5.0 μm (690 GB per specimen, 
Figure 4.5 in Supplementary Materials) [31]. Three images of each specimen were collected 
using different fluorescent filter sets: one channel to visualize bone tissue (350/420 nm, Ex/Em), 
and one for each of the two fluorescent markers of damage zones (xylenol orange - 545/620 nm, 
calcein - 470/525 nm).  Images collected were segmented by a trained observer and underwent 
three-dimensional binary morphological operations. Propagating damage zones were identified 
as regions where the second damage stain was in direct contact with the first damage stain. 
Remodeling cavities on the bone surfaces were detected by irregular surface texture and traced 
manually in three dimensions [32]. Spatial correlations between damage zones and remodeling 
cavities were determined as the ratio of damage volume near remodeling cavities (within 8 μm) 
to that of bone volume selected at random that was found to be near remodeling cavities [33]. 
The characteristic size of each damage zone (c = cubed root of damage zone volume) was 
determined at the end of the first bout of loading (cinitial) and at the end of the second bout of 
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loading (cfinal) and the growth rate was determined as follows: 
secondboutN
cc
dN
dc initialfinal  ,  
where Nsecondbout is the number of cycles applied between the first and second bouts of loading. 
4.4.4. Finite Element Modeling and Damage Propagation 
  Three-dimensional images of each specimen, collected prior to loading using 
microcomputed tomography (10 μm voxels), were used to generate linear elastic finite element 
models. Each finite element model consisted of 31-98 million elements and was implemented on 
the Stampede Supercomputer Cluster (Texas Advanced Computing Center) [34]. The tissue 
Young’s modulus for each model was selected so that the stiffness of the finite element model 
matched that of the apparent Young’s modulus determined experimentally (tissue Young’s 
modulus 13.74 ± 3.25 GPa, mean ± SD). Compression applied at the apparent scale (millimeters) 
resulted in local regions of compression and tension (Figure 4.13 in Supplementary Materials). 
The average von Mises stress within each damage zone, along with damage zone length, c, was 
used to calculate ΔK. Similar results were achieved with other scalar assays of tissue stress/strain. 
4.4.5. Advanced Glycation End Products (AGEs) 
Five cylindrical cores of cancellous bone from the same donor pool (2 male, 3 female, 
aged 67-88 years) were analyzed for fluorescent AGEs.  Specimens were decalcified in a 
sodium citrate-formic acid solution and then dehydrated. Following dehydration, samples were 
embedded in paraffin, and 6 μm thick transverse sections were mounted onto slides. AGEs were 
observed by auto fluorescence in 5 sections per sample using a confocal microscope (Zeiss 710, 
405/488 nm, Ex/Em) with uniform exposure time (150 ms). Bright field images were used to 
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normalize brightness among fields of view. Images were analyzed using Image J (developed at 
the U.S. National Institutes of Health).  
4.5. Results 
4.5.1. Fatigue Crack Growth within Trabeculae is Primarily Driven by Damage Size and Not 
Local Tissue Stress 
We examined the propagation of tissue damage within cancellous bone (Figure 4.1A) 
from the fourth lumbar vertebral bodies of 11 human donors (4 male, 7 female, aged 62-88 
years). Cylindrical specimens of cancellous bone were submitted to cyclic compression in two 
bouts of loading. After each bout of loading specimens were stained for tissue damage (first with 
xylenol orange then with calcein, Figure 4.1B). The applied loading brings the cancellous bone 
specimen into the tertiary phase of the creep-fatigue curve but does not cause overt failure 
(specimens remain intact). Three-dimensional fluorescent images of the entire cancellous bone 
microstructure (8 mm diameter, 4 mm in height) were collected using epifluorescence-based 
serial milling at a voxel size sufficient to observe tissue damage (0.7 × 0.7 × 5.0 μm voxels, see 
Materials and Methods and Figure 4.5 in Supplementary Materials). The tissue damage 
examined consisted of microscopic cracks as well as regions of submicroscopic cracking, which 
together we refer to as “damage zones.” The use of sequential staining made it possible to 
observe the propagation of damage zones in cancellous bone in situ. We found that 87% of the 
tissue damage generated during the second bout of loading was due to expansion of an already 
existing damage zone (i.e. propagation, Figure 4.1C, Table 4.1 in Supplementary Materials) 
rather than the initiation of a new damage zone. 
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Figure 4.1. (A) A three-dimensional image of cancellous bone with tissue damage stained is 
shown. Propagating damage zones display green stain extending from orange stain. (B) The 
minimum and maximum strain per cycle is shown. Cyclic compressive loading was applied to 
cancellous bone specimens until the start of the tertiary phase of fatigue and a fluorescent stain 
(orange) was applied to mark damage zones. Cyclic loading was reinstated until 5% applied 
strain and a second fluorescent stain (green) was applied. (C) 87% percent of the damage volume 
in the second bout of loading had propagated from pre-existing damage.  
 Damage growth rates (dc/dN, m/cycle) and local stress intensity factor range (ΔK, 
MPa√m) were determined using the characteristic size of each damage zone (c = the cubed root 
of damage zone volume) after each bout of loading, the number of cycles between the two bouts 
of loading and the local stress range (von Mises) determined from high-resolution finite element 
models (10 μm elements, 31-98 million elements/model, see Methods, Figure 4.2A). Damage 
growth rate was assessed once at each of the 49-287 damage zones in each specimen (1,676 
damage zones in 11 specimens). This approach differs from traditional fatigue crack growth, 
which performs multiple measures of crack growth rate during advance of a single crack, an 
analysis which, to our knowledge, has been performed on only a few dozen cracks in cortical 
bone [35-37]. The observed damage zone propagation was consistent with the stable crack 
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growth rates of small cracks in cortical bone (Figure 4.2D, Figure 4.6 in Supplementary 
Materials). Damage zone growth rate, however, was positively correlated with local stress 
intensity factor range within each donor (R2= 0.51, p < 0.001), although large inter-individual 
variations were observed (color labels on Figure 4.2D). Damage zone growth rate was closely 
related to initial damage zone size (Figure 4.2C) and, interestingly showed little relationship to 
local cyclic stress range (Figure 4.7 in Supplementary Materials). Larger damage zones were 
more likely to propagate during the second bout of loading; on average, 72% of damage zones 
created during the first bout of loading went on to propagate during the second bout of loading 
(Figure 4.8 in Supplementary Materials). 
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Figure 4.2. Fatigue crack growth within cancellous bone. (A) The distribution of von Mises 
stress within trabecular bone is shown. (B) Regions of greatest tissue stress were located at 
surfaces of trabeculae, suggesting that trabeculae experience bending and torsional loading. (C) 
Damage zone growth rate is expressed as the rate of change in damage zone size, c, divided by 
the applied number of cycles, N. Damage zone growth was strongly correlated with the size of 
the damage zone present before the second bout of loading (p < 0.001), but showed no 
correlation to local cyclic stress (R2 = 0.006) (Figure 4.7 in Supplementary Materials). (D) Data 
from the current study (colored points) is shown overlaid with fatigue crack growth measured in 
cortical bone (a summary of the literature from [35]). Positive relationships between crack 
growth rate (experimental data) and stress intensity range (finite element model data and 
experimental data) were observed within each specimen (p < 0.001). Data points with the same 
colors are from the same specimen. 
 To further understand the limited association between local tissue stress and damage 
propagation, we determined the local tissue stresses at damage zones (Figure 4.9A in 
Supplementary Materials). The struts within cancellous bone commonly experience bending and 
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torsional loads, leading to the greatest tissue stresses at strut surfaces [38]. Tissue stresses at strut 
surfaces were greatest on the surfaces of trabeculae (Figure 4.2B, Figure 4.9B in Supplementary 
Materials). However, the majority of tissue damage (68%) occurred in the central regions of 
trabeculae. Damage zone propagation also occurred predominately in the interior of the 
trabeculae (Figure 4.3C). Rupture of individual trabeculae, also known as trabecular 
microfracture, was rarely observed. The percent of trabeculae in a specimen that ruptured ranged 
from 0.06-1.32% (0.47 ± 0.36%, mean ± SD), demonstrating that failure of individual struts was 
not a common occurrence. In summary, these results demonstrate that damage formed and 
propagated in the interior of struts despite the fact that the tissue level stresses were greater at 
surfaces than the interior.  
 
Figure 4.3. Tissue damage caused by fatigue loading is distant from stress concentrations 
generated by bone remodeling. (A) Remodeling cavities were traced manually and (B) damage 
zones were less likely to be near cavities than regions selected at random (the ratio is less than 
1.0). (C) Damage initiated and propagated primarily in the interstitial regions in the center of 
trabeculae (more than the average depth of remodeling events, 30 μm). 
4.5.2. Stress Concentrations on Trabecular Surfaces 
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To confirm our finding that local tissue stress was poorly correlated with damage 
propagation, we tested the idea that stress concentrations on the trabecular surfaces caused by 
bone remodeling were preferential locations of damage initiation and propagation. When old or 
damaged bone tissue is removed during bone remodeling, a cavity is generated on the trabecular 
surface that can increase local stresses by more than an order of magnitude [20], an increase 
expected to promote damage initiation and propagation [39]. However, we found remodeling 
cavities (54-111 per specimen, Figure 4.3A) were preferentially distant from damage zones 
(Figure 4.3B). One possible explanation is that trabeculae with cavities experience less stress 
because load is distributed preferentially to more robust trabeculae that do not have cavities. 
Additionally there is evidence that the generation of remodeling cavities in vivo occurs primarily 
on trabeculae experiencing less load [40]. However, in our analysis, stresses at remodeling 
cavities were similar to those at other trabecular surfaces (Figure 4.10 in Supplementary 
Materials) demonstrating that trabeculae with cavities were not under-loaded. Hence we 
conclude that geometric discontinuities associated with the cavities did not lead to the creation or 
propagation of damage zones. To further assess the unexpected negative correlation between 
cavities and damage zones, we repeated our analysis considering only the cavities with the 
largest gross stress concentration factor (greatest ratio of cavity depth to strut thickness). The 
deepest cavities were even less likely to be near damage zones when compared to all of the 
cavities (p < 0.05, Figure 4.11 in Supplementary Materials). The results indicate that geometric 
discontinuities such as remodeling cavities have little effect on damage zone initiation or 
propagation. 
4.5.3. Patterns of Tissue Damage Reflect Accumulation of Advanced Glycation End products 
(AGEs) 
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To determine if patterns of material heterogeneity were consistent with regions of damage 
propagation, we determined the distribution of advanced glycation end products in cancellous 
bone from the same donor cohort. AGEs accumulate in bone tissue over time, and are found in 
higher concentrations in regions of bone tissue that has been present in an individual for a longer 
period of time. AGEs have been associated with non-enzymatic collagen cross-linking and 
increased tissue level brittleness [41, 42]. Higher concentrations of fluorescent AGEs were 
present in the central regions of the trabeculae (Figure 4.4). In summary, the presence of 
fluorescent AGEs, a factor associated with reduced ductility, was greater in the same regions 
where microscopic tissue damage was more likely to occur.  
 
 
Figure 4.4. Advanced Glycation End products (AGEs) in cancellous bone are primarily found 
distant from the trabecular surface. (A) Fluorescence image of decalcified human vertebral 
cancellous bone. Regions of increased brightness indicate accumulation of advanced glycation 
end products. (B) The pixel intensity 40 μm or more away from the surface (blue) and within 20 
μm of the bone surface (green) for a donor. The brightest regions were more than 40 μm away 
from the surface indicating high AGE content occurs primarily in the center of trabeculae. 
4.6. Discussion 
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This work provides the first experimental analysis of damage propagation within the 
struts of an open-cell foam. The findings demonstrate that accumulation of tissue damage in 
cancellous bone is predominately the result of propagation from previously existing damage and 
that propagation of tissue damage occurs distant from regions of high stress due to material 
heterogeneity. As a result, the likelihood that a damage site will propagate is related to damage 
zone size instead of the magnitude of the local stress. Small damage events are less likely to 
propagate, while all large damage sites propagate. The results are consistent with the concept that 
failure of cancellous bone under fatigue is a localized process; once damage forms in a location; 
additional accumulation of tissue damage is a result of propagation rather than the initiation of 
new damage sites.  
Stress concentration features that are physically small can be ineffective at initiating 
cracks [43], a fact that would suggest that the locations of damage zones might be indifferent to 
the presence of remodeling cavities. Damage zones were not found near remodeling cavities; 
instead we found that damage propagation was preferentially distant from surfaces with 
remodeling cavities, implying that differences in tissue material properties at surfaces and the 
interior are dominating damage propagation. The accumulation of tissue damage in the centers of 
trabeculae is also consistent with variation in material properties between material at the surface 
and the interstitial material in the interior of trabeculae. The central interstitial regions of 
trabeculae have been present longer in the body because bone remodeling initiates at trabecular 
surfaces. Tissue present in the body longer accumulates greater amounts of advanced glycation 
end products (AGEs) and associated increases in collagen cross-links as well as altered in 
mineral composition (increased degree of mineralization and crystallinity), traits that have been 
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associated with increased hardness [44, 45], increased brittleness [42], and reduced ductility [9, 
14] of bone material. The current study directly demonstrates increased accumulation of AGEs in 
the centers of trabeculae suggesting that reductions in ductility and fracture toughness associated 
with increased non-enzymatic collagen cross-linking are the likely causes of observed damage 
patterns. Hence, our observations that damage zones initiate and propagate preferentially distant 
from cavities and strut surfaces are consistent with the idea that material heterogeneity, 
specifically increased surface ductility compared to the interior of trabeculae, directs damage 
propagation. 
The observation that cancellous bone displays a more ductile surface and less ductile 
center was surprising in that it contrasts with surface treatment strategies used to increase fatigue 
life of man-made materials via surface hardening treatments [46]. The presence of a more ductile 
surface provides two key functional advantages to a biological foam. First, the presence of more 
ductile trabecular surfaces makes the material less sensitive to surface flaws and stress 
concentrations that are unavoidable in biological materials. Without this pattern in tissue 
heterogeneity, stress concentrations caused by self-healing processes such as bone remodeling 
could promote failure in cancellous bone. Hence, our findings contradict a long—held 
assumption that cavities generated by the activity of osteoclasts during the bone remodeling 
process weaken cancellous bone [39, 47]. Second, the presence of a more ductile strut surface 
forces tissue damage and associated permanent deformations into strut centers. Deformations in 
struts caused by bending and torsion (the primary loading modes experienced by trabeculae) are 
small near strut centers (neutral axis/center of twist). As a result, permanent deformations caused 
by tissue damage in strut centers are much smaller than would be expected if damage were 
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instead present at strut surfaces. Upon unloading, struts that accumulate tissue damage in the 
center (where stresses are lower) will recover more deformation from bending and torsion than 
struts accumulating damage at surfaces. Improved recovery of deformation of individual struts 
then leads to improved recovery of deformation of the entire foam structure.  
Cancellous bone has long been recognized for the ability to recover large amounts of 
deformation after an overload; specimens compressed well beyond ultimate strain typically 
recover 61-94% of applied deformation [48-50]. The ability to recover deformation in cancellous 
bone allows for recovery of shape of whole bone after a fracture, and is therefore a passive 
mechanism of “setting” or reducing a fracture. By immediately recovering deformation of the 
whole bone, subsequent self-healing will maintain a structure more similar to the initial bone 
shape and lead to better function post-injury [48].  
The ability of cancellous bone to recover deformation after failure provides a compelling 
answer to a long-standing question: why do bones have foam-like regions at all? A common 
explanation for the presence of a foam core in bone is to improve flexural and torsional rigidity 
and prevent buckling (crimping) [2]. However, in long bones the foam-like cancellous bone is 
present at the ends of the bones near the joints where they would provide relatively little 
contribution to flexural rigidity and resistance to buckling. The second common explanation for 
the presence of cancellous bone is improved energy absorption at joints, but energy absorption 
per unit mass is less in cancellous bone than in solid cortical bone [51].  In contrast, recovery of 
bone shape after fracture, especially at the joints where cancellous bone is most common, is key 
to enabling effective healing and locomotion after mechanical failure. We suggest that 
cancellous bone does not so much improve stiffness, strength and energy absorption, but 
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improves performance of the whole bone after failure. 
The observed failure mechanisms of cancellous bone provide an attractive strategy for the 
design of biomimetic materials. Additive manufacturing techniques have achieved materials with 
designed microstructures that display large amounts of deformation recovery [3]. These 
strategies, however, concentrate on microstructural heterogeneity and mechanical performance 
prior to failure but do not necessarily consider material heterogeneity and performance of the 
component after failure has occurred [1, 2]. Lightweight, man-made components utilizing foams 
treated to increase surface ductility have the potential to continue to provide some mechanical 
function after overt failure, thereby providing longer service life in cases where replacement and 
repair are not immediately possible. 
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Table 4.1. Damage volume fraction measurements  
Damage Measure  Mean ± SD 
Total damage volume fraction (1st + 2nd bout, DV/BV, %) 5.13  ± 2.04 
1st bout damage volume fraction (DV/BV, %) 0.96  ± 0.58 
2nd bout initiated damage volume fraction (DV/BV, %) 0.41  ± 0.24 
2nd bout propagated damage volume fraction (DV/BV, %) 3.45  ± 1.74 
 
 
Figure 4.5. Serial milling imaging of microdamage is shown. Fluorescent light images of bone 
were acquired using UV excitation/emission (350/420 nm), with voxel sizes of 0.7×0.7×5.0 μm. 
Raw images were collected using this resolution consist of 800 transverse cross-sections, each 
consisting of a 6×6 mosaic of images. 
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Figure 4.6. The distribution of damage zone growth rate for all specimens is shown. All but a 
few damage zones grew at rates within the range of small crack growth observed in cortical bone 
[35].  
 
Figure 4.7. Damage zone growth rate collected from the experimental data was not related to 
local tissue stresses calculated from the finite element models (R2 = 0.006). Data points with the 
same color are from the same specimen. 
  
142 
 
 
Figure 4.8. Probability of damage zone propagation during the second bout of loading is shown 
(mean ± SE). Larger microdamage sites were more likely to propagate. The overall average 
proportion of damage zones propagating was 0.72. 
 
Figure 4.9. (A) Stresses of damage zones at the surfaces of trabeculae are greater compared to 
the center of trabeculae (p < 0.01). (B) Stresses at the surfaces of trabeculae are greater than at 
the center of trabeculae (p < 0.01). 
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Figure 4.10. Stresses at remodeling cavities were not different from those at other regions of the 
surface at the resolution of the finite element models (p = 0.82, paired t-test), demonstrating that 
trabeculae with cavities were experiencing loads similar in magnitude to those at other regions of 
the microstructure. 
 
Figure 4.11. The deepest cavities (with greatest gross stress concentration factor) were even less 
likely to be near damage zones when compared to all of the cavities (p < 0.05).  
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Figure 4.12. (A) Initial Young’s modulus, E0. Linear regression model of initial Young's 
modulus as a function of bone volume fraction (R2 = 0.28). (B) Reductions in Young’s modulus 
during fatigue loading. The reduction in young’s modulus for the first bout of cyclic loading is 
shown in black, and the second bout of cyclic loading is shown in gray. A negligible reduction in 
Young’s modulus was caused by interruption of loading (as indicated by the arrow).  
 
Figure 4.13.  The distributions of maximum principal stress in tension and compression are 
shown. Although the specimen was loaded in apparent compression, regions of local tensile 
stress develop due to bending of trabeculae. 
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CHAPTER 5                                                      
AN IN VIVO MODEL OF A MECHANICALLY-INDUCED BONE MARROW 
LESION 
 
The following chapter has been submitted for publication. The article is titled “An In 
Vivo Model of a Mechanically-Induced Bone Marrow Lesion” by Matheny JB, Goff 
MG, Pownder SL, Koff MF, Hayashi K, Yang X, Bostrom MPG, van der Meulen 
MCH, Hernandez CJ. 
  
  
152 
 
5.1. Abstract 
Bone marrow lesions (BMLs) are radiologic abnormalities in magnetic resonance 
images of subchondral cancellous bone and have been correlated with the 
development of osteoarthritis. Little is known about the physiologic processes within a 
BML, but BMLs are often associated with mechanical stress, bone tissue 
microdamage and increased bone remodeling. Here we establish a rabbit model to 
study the pathophysiology of BMLs. We hypothesized that in vivo loads that generate 
microdamage in cancellous bone would also create BMLs and increased bone 
remodeling. Cyclic loads (0.2 to 2.0 MPa in compression for 10,000 cycles at 2 Hz) 
were applied to cancellous bone in vivo (n = 3 animals, right limb loaded, left limb 
controls experienced surgery but no loading). Magnetic resonance images were 
collected using STIR and T1 weighted sequences at 1 and 2 weeks after 
surgery/loading and histological analysis of the BML was performed after euthanasia 
to examine tissue microdamage and remodeling. Loaded limbs displayed BMLs larger 
than unloaded controls (p = 0.01). Histological analysis of the BML at 2 weeks after 
loading showed increased tissue microdamage (p = 0.03) and bone resorption (p = 
0.01). The rabbit model described here displays the hallmarks of load-induced BMLs, 
supporting the use of the model for more detailed studies of the development, 
progression and treatment of BMLs. Clinical evidence suggests that BMLs may be an 
early indicator of, or contributor to, cartilage degeneration. The current study provides 
an animal model to understand the pathophysiology of BMLs. 
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5.2. Introduction 
Bone marrow lesions (BMLs) or “bone marrow edema patterns” occur due to 
chronic and acute joint disorders and manifest as an increase of signal intensity in 
water sensitive magnetic resonance imaging sequences in subchondral cancellous 
bone. In longitudinal studies the presence and growth of bone marrow lesions are 
associated with increased risk of joint degeneration leading to total joint arthroplasty 
[1-3]. Bone marrow lesions have been observed in patients prior to clinical symptoms 
of osteoarthritis and, unlike articular cartilage degeneration, may be reversible raising 
the possibility that bone marrow lesions may be an indicator of early stage 
osteoarthritis or even a therapeutic target to prevent cartilage degeneration [4-7]. 
The etiology and pathophysiology of bone marrow lesions is poorly 
understood, but appears to be associated with mechanical stresses in cancellous bone. 
Bone marrow lesions associated with osteoarthritis occur in regions of subchondral 
bone experiencing greater habitual stresses [8, 9]. Biopsies of bone marrow lesions 
acquired at the time of total joint arthroplasty show microscopic cracks and other 
tissue damage [10] as well as increased bone remodeling [11], woven bone formation, 
and increased angiogenesis [12]. These findings are consistent with the idea that bone 
marrow lesions involve mechanically-induced tissue damage and bone remodeling. 
However, a limitation of biopsies is that they are acquired at the time of total joint 
replacement and therefore provide little information about the sequence of events in 
the early, reversible stages of bone marrow lesions. 
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Given the challenges in characterizing the pathophysiology of early stage bone 
marrow lesions in patients, a pre-clinical model that recapitulates the pathogenesis of a 
bone marrow lesion would be valuable for understanding the natural history of bone 
marrow lesion development and progression. In rodents, transection of the anterior 
cruciate ligament can result in bone marrow lesions [13] and tissue microdamage [14] 
prior to cartilage degeneration. Additionally some rodent studies have associated 
increased bone remodeling with subsequent articular cartilage degradation [13, 14]. 
These findings are consistent with long standing theories that load-induced 
microdamage and increased bone remodeling contribute to the pathogenesis of 
osteoarthritis [15, 16]. While rodent models are useful for studying surgically-induced 
cartilage degeneration, regions of cancellous bone in mice and rats are small, limiting 
our ability to characterize the biological and mechanical processes within a bone 
marrow lesion. In addition, the small anatomy frequently prevents the use of non-
invasive imaging using clinical equipment, hampering translation to the clinical 
setting. 
The goal of this line of investigation was to understand the pathophysiology of 
bone marrow lesions. Here we establish an animal model of mechanically-induced 
bone marrow lesions focusing on two specific hypotheses. First, we hypothesized that 
the loads required to generate microdamage in subchondral cancellous bone would 
also create bone marrow lesions. Second, we hypothesized that regions of cancellous 
bone receiving cyclic loading and forming bone marrow lesions would correspond 
with increased bone remodeling. The initiation and progression of bone marrow 
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lesions will be evaluated using non-invasive, clinical field strength MRI, and the 
amount of microdamage and bone resorption will be evaluated histologically 
following euthanasia.  
5.3. Materials and Methods 
Given the association between mechanical loading and bone marrow lesions, 
we adapted an in vivo loading model in the rabbit to generate a bone marrow lesion. 
The rabbit loading model has been used extensively to study functional adaptation in 
cancellous bone [17-19] and implant osseointegration [20-22]. In the model, an 
implant is placed on the lateral distal femur. The cortex under the implant is removed, 
and mechanical loads are applied directly to the epiphyseal cancellous bone through a 
loading core (Figure 5.1).  
 
Figure 5.1. The rabbit in vivo loading device is shown. A PEEK implant (gold) was 
surgically fixed to the lateral epiphysis of the distal femur by Titanium and PEEK 
bicortical screws. The cortex below the implant was removed allowing for cyclic 
compressive loads to be applied to the underlying cancellous bone by the loading core. 
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Loads were applied for 10,000 cycles at 2 Hz immediately following device 
implantation. The loading core was removed prior to closing the surgical site. 
In the current implementation, the loading device was implanted by a board 
certified veterinary surgeon (KH). Prior to implantation, a 17 mm x 9 mm region of 
the cortex located distal to the lateral femoral growth plate were ground flat using 6.5 
and 5 mm spherical cutting burrs. A polyether ether ketone (PEEK) implant was 
placed on the lateral epiphyseal cortex of the distal femur. The implant was secured to 
the femur using a 2 mm diameter PEEK screw and a 1.5 mm diameter titanium screw 
(see Figure 5.1). The use of PEEK implants avoids metallic susceptibility artifact 
during magnetic resonance imaging (MRI) of tissues immediately adjacent to the 
implanted material. Following placement of the implant, the cortex (1 mm thickness) 
beneath the implant was removed using a custom routing device (diameter 4.75 mm). 
An aluminum loading core aligned with the implant was placed through the hole in the 
cortex and cyclic loading was applied directly to the underlying cancellous bone using 
a servo-electric loading device (Testbench, Bose Electroforce) (Figure 5.1).  
5.3.1 In Vivo Loading and Visualization of Bone Marrow Lesions 
Animal experiments were performed following approval by the Cornell 
University Institutional Animal Care and Use Committee in an AAALAC-accredited 
facility. Male, New Zealand white rabbits (n=3, 7.5 months old, 3.56±0.42 kg, 
Covance Inc., Princeton, NJ) were housed individually in stainless steel cages in a 
room with a 12:12 hour light: dark cycle and temperature between 18.9 to 21.1 °C. 
Rabbits were fed Teklad 15% rabbit diet 8630 (Envigo, Madison, WI) and water ad 
libitum and provided environmental enrichment. Following 2 weeks of acclimation, 
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animal were anesthetized with isoflurane and the implants were placed bilaterally 
using a posterior lateral surgical approach. The right limbs received implants and were 
loaded in cyclic compression between 0.2 MPa (minimum) and 2.0 MPa (maximum) 
at 2 Hz frequency for 10,000 cycles. The left limb received an implant but no load was 
applied. Prior to closing the surgical site, a PEEK cap was secured within the implant 
to occupy the hole in the cortex. Wounds were washed with antiseptic, and an 
antibiotic prophylaxis was applied the day of surgery (25 mg/kg ampicillin). Rabbits 
received buprenorphine (0.05 mg/kg) analgesic for 2 days after surgery.  
At one and two weeks after surgery/loading, animals were anesthetized, and 
both limbs were evaluated using a clinical 3T MRI scanner (DVMR 750, GE 
Healthcare, Milwaukee WI) with an 8 channel phased-array transmit/receive (T/R) 
knee coil (Invivo, Gainesville, FL). T1-weighted and fat-suppressed short tau 
inversion recovery (STIR) images were collected to visualize BMLs. BMLs were 
identified and manually segmented by a board certified veterinary radiologist (SLP) 
using a combination of the STIR and T1 weighted images. BML volume (in mm3) was 
calculated as the area of the BML within individual slices multiplied by slice thickness 
[2, 23]. Animals were euthanized via an intravenous injection of pentobarbital sodium 
(86 mg/kg FatalPlus, Vortech Pharmaceuticals, Dearborn MI) immediately following 
acquisition of the second MRI dataset. 
Following euthanasia, the limbs were dissected free from soft tissue, implants 
were removed, and microcomputed tomography images of each femur were collected 
at an isotropic voxel size of 50 μm (eXplore CT-120, GE Healthcare, Milwaukee WI). 
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The lateral epiphysis of each femur was dissected using a low speed precision saw 
(IsoMet Low Speed Saw, Buehler, Lake Bluff, Illinois USA), and bone marrow was 
removed using a low-pressure water jet. To identify microscopic tissue damage, 
specimens were bulk stained in calcein solution (0.5 mM) for two hours under 
vacuum. Specimens were then embedded undecalcified in polymethyl- methacrylate, 
and sections from the coronal plane were collected and polished to 100 μm thickness. 
Images of the sections were obtained using a confocal microscope (Zeiss LSM 710 
Confocal Carl Zeiss, Inc., Thornwood, NY USA) to obtain a mosaic of images (4.08 × 
4.08 mm), 2.4 μm thick, with a pixel size of 0.66 μm. A rectangular region of interest 
(width 3.0 mm, height 3.7 mm) located 500 microns away from contact with the 
loading core was selected for analysis. Damage volume fraction (DV/BV, %), and 
eroded surface (ES/BS, %), identified as scalloped or crenated surfaces, were 
measured using point counting (21 μm grid spacing). The MR images, microcomputed 
tomography images and histology sections were aligned with each other in three 
dimensions using commercial software to allow co-localization between trabecular 
microstructure, histology and MRI (Amira, version 5.3, Visage Imaging, San Diego, 
CA, USA).  
All analyses were conducted using automated approaches or by trained 
observers blinded to specimen loading history. The current study builds on prior pilot 
studies (see Figures 5.5 – 5.7 in Supplementary Materials) in which the cyclic loading 
parameters were identified and shown to generate tissue microdamage in cancellous 
bone without causing overt fracture. Additionally, the time period of applied loading 
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(83 minutes) was within a reasonable duration of anesthesia (as viewed by veterinary 
staff and KH). 
5.3.2. Statistical Analysis 
 Differences in damage volume fraction and eroded surface between loaded and 
unloaded groups were identified using two-tailed, paired t-tests (JMP Pro 10.0.2, SAS 
Institute Inc., Cary, NC, USA). The effect of in vivo loading on BML volume was 
determined using repeated measures ANCOVA implemented with a generalized least 
squares model using time and limb (loaded, non-loaded) as fixed effects and animal as 
a random effect. Data are presented as mean ± SD.  
5.4. Results 
Following surgery and cyclic loading in vivo, BMLs were apparent in loaded 
limbs in both STIR and T1 weighted MR sequences at one and two weeks after 
surgery/applied loading (Figure 5.2). BMLs were present in loaded limbs and small 
BMLs were present in control limbs. BMLs in loaded limbs were larger in volume 
and extended farther from the surface of applied loading than the BML signal in 
control limbs (Figure 5.3). BML volumes were 26.27 ± 19.13 mm3 one week after 
loading and 35.97 ± 11.49 mm3 two weeks after loading. In contrast, BMLs in 
control limbs were smaller than BMLs in loaded limbs (p=0.01 vs. loaded volumes, 
9.60 ± 10.87 mm3 and 10.97 ± 3.68 mm3 at one and two weeks, respectively). The 
signal in the control limbs appeared closer to the surface and was likely associated 
with the surgery induced damage on the surface.  
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Figure 5.2. In vivo cyclic loading applied to epiphyseal cancellous tissue of the 
distal femur of the rabbit induced the formation of bone marrow lesions evident 1 
and 2 weeks after loading. T1 weighted and STIR MR images collected at 1 and 2 
weeks after surgery/loading. Bone marrow lesions in the loaded limbs are indicated 
with arrows. 
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Figure 5.3. BMLs in loaded limbs were larger in volume and extended farther from 
the surface of applied loading than the BML signal in adjacent to surgery in control 
limbs. (A-B) MicroCT images overlaid on STIR MR images collected at 2 weeks 
after loading are shown. The BML in loaded limbs (magenta) and BML signal in 
control limb (blue) are shown. (C) A three-dimensional reconstruction of a microCT 
data set from a loaded limb is shown with partial transparency to enable 
visualization of the bone marrow lesion (BML, magenta) in relation to the location 
of applied loading (white circle). (D) BML volume was larger in loaded than in 
control limbs.   
Bone tissue collected from BMLs had tissue microdamage and evidence of 
increased osteoclast activity at two weeks after surgery/loading (Figure 5.4A-C). 
Loaded limbs had substantially more calcein-stained microdamage (damage volume 
fraction: Loaded 3.7 ± 0.3% vs. Control 0.7 ± 0.7%, p = 0.03, see Figure 5.4D) and 
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evidence of greater osteoclast activity (eroded surface: Loaded 17.2 ± 2.72% vs. 
Control 6.21 ± 1.95%, p = 0.01, see Figure 5.4E) compared to contralateral control 
limbs. The amount of calcein-stained microdamage was correlated with BML 
volume (R2 = 0.85, p<0.009, see Figure 5.4F). 
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Figure 5.4. Bone tissue collected from BMLs had tissue microdamage and evidence 
of increased osteoclast activity when evaluated two weeks after surgery/loading (A) A 
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microCT image of a loaded limb with an overlay of the MR image of the BML 2 
weeks after loading is shown. The white box indicates the location of the histology 
section shown in (B) with magnified section shown in (C). (C) Microdamage (stained 
with calcein, green arrows) and eroded surfaces (white arrows) were evident in the 
histology sections of the loaded limbs. Baseline levels of microdamage and 
remodeling were very low in the contralateral control limbs. (D-E) Eroded surface and 
damage volume fraction and eroded surface were greater in loaded limbs. (F) The 
direct assessment of damage volume fraction was correlated with indirect MRI 
assessment of BML volume at two weeks after loading.  
5.5. Discussion 
The goal of the current study was to establish a preclinical model of a BML 
utilizing indirect and direct imaging modalities to evaluate the development and 
progression of BMLs. We showed that in vivo cyclic mechanical loading of the 
cancellous bone in the lateral distal femur of the rabbit generated a BML visible at 1 
and 2 weeks following loading. Regions of bone tissue within the bone marrow lesion 
contained tissue microdamage and increased bone resorption as detected by eroded 
surface. These features recapitulated the hallmarks of bone marrow lesions observed 
in clinical biopsies.  
A limitation of the current study is the small sample size (n=3 paired limbs). 
Although the number of limbs examined was small, the differences between loaded 
and control limbs were large and consistent among all three animals, providing 
confidence in the repeatability of the model. We examined histology at a single time 
point; therefore, our results provide only rudimentary information regarding the 
longitudinal changes of the bone. Our data show that the current model is useful for 
examining load-induced BMLs, but our fatigue damage-based approach may result in 
a bone marrow lesion that differs from those associated with inflammation, 
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periarticular bone infarcts and transient idiopathic BMLs [24]. Little is known about 
the etiology of BMLs, the pathophysiology of a load-induced BML may not be 
representative of other types of BMLs. However, increased mechanical stress in the 
joint is implicated in most BMLs associated with osteoarthritis [8, 9], and our model 
recapitulates the histopathology of human BMLs including tissue damage [10] and 
bone remodeling [11, 12]. The current study concentrated on evaluating the 
pathogenesis of BMLs, but we anticipate that concomitant changes would occur at the 
adjacent articular surfaces that may also be evaluated using morphologic and 
quantitative MRI [25, 26]. Other approaches for studying BMLs in the context of 
cartilage degeneration are available in mice and rats [13]. Compared to rodent models, 
the rabbit model is advantageous for studying BMLs in bone because of larger regions 
of cancellous bone and fusion of the growth plates at a younger age [27], thereby 
providing an environment in epiphyseal cancellous bone that more closely mimics the 
conditions in human bone marrow lesions. 
The presence of tissue microdamage and increased bone resorption in BMLs is 
consistent with prior work examining interactions between microdamage and 
remodeling. Tissue microdamage has long been considered a stimulus for bone 
resorption and remodeling. In cortical bone, the generation of tissue microdamage 
causes apoptosis of neighboring osteocytes leading to increased bone resorption and 
remodeling [28, 29]. In cancellous bone, the response to tissue microdamage is 
unknown and may also involve increased bone resorption. However, tissue damage in 
cancellous bone has also been associated with increased bone formation in the form of 
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a “microcallus” [30]. While the current study demonstrated increased bone resorption 
within the BML, as measured by eroded surface, the use of only a single time point for 
histology and the absence of bone formation markers prevent us from making 
conclusions regarding the bone remodeling response to tissue damage. A larger study 
with additional time points would be required to determine the temporal progression 
of load-induced microdamage in cancellous bone. A spatial and temporal relationship 
between microdamage and subsequent bone resorption/formation would indicate the 
importance of tissue microdamage as compared to other effects of loading (e.g. 
increased marrow pressure, etc.) in stimulating bone remodeling. Spatial and temporal 
associations between tissue damage and remodeling have been performed in cortical 
bone [29, 31], but demonstrating such a relationship in cancellous bone is more 
difficult because spatial correlations can occur out of the plane of a histology section, 
requiring the use of three-dimensional imaging of remodeling and microdamage [32].  
The pre-clinical model described here has a number of strengths as a tool for 
studying BMLs. First, the model includes two characteristics that are observed in 
biopsies of established BMLs in humans: tissue microdamage and evidence of 
increased bone remodeling based on increased eroded surface. Second, BMLs in this 
animal model were created by applying loads directly to epiphyseal cancellous bone, 
allowing examination of the BMLs without direct damage to cartilage or ligaments. 
Lastly, as mentioned above, a strength of the model is the use of skeletally mature 
rabbits with closed growth plates to ensure that changes in cancellous bone 
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microarchitecture were due to the applied mechanical stimulus and not longitudinal 
growth [33]. 
Clinical evidence suggests that BMLs may be an early indicator of, or 
contributor to, articular cartilage degeneration. Recent studies have proposed clinical 
treatments for BMLs such as bisphosphonates [34], chondroitin sulphate [35] and 
subchondroplasty [36]. Because our understanding of the pathophysiology of BMLs is 
limited, the most effective treatment strategy is unclear, as is how best to evaluate the 
effectiveness of a given treatment. By representing the major components of a clinical 
BML, this in vivo rabbit model has the potential to provide important information on 
the natural history and efficacy of treatments on load-induced BML development and 
progression. 
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5.7. Supplemental Materials 
A series of pilot studies were performed on rabbit cadaver limbs to identify a 
cyclic loading regimen that would generate tissue microdamage in cancellous bone, 
thereby mimicking tissue microdamage observed in biopsies from patients. Generating 
tissue microdamage in bone is a balance between load amplitude and the number of 
applied cycles of loading [37]. Excessive load amplitude will cause overt failure of 
cancellous bone, but excessively small load amplitudes will only generate tissue 
microdamage following an excessive period of cyclic loading. To determine the 
appropriate balance between load magnitude, number of cycles and tissue 
microdamage, we performed pilot studies on rabbit femora dissected free of soft 
tissues. A compressive cyclic load ranging from 0.2 to 2.0 MPa (minimum to 
maximum) at 2 Hz frequency for 10,000 cycles was found to reliably generate tissue 
microdamage in vitro (Supplemental Figure 1). The duration of applied loading (83 
minutes) was considered appropriate for anesthetic as viewed by veterinary experts.  
To confirm that the selected loading regimen would reliably generate tissue 
microdamage when soft tissues were intact, the implant was implanted on rabbit limbs 
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(n=5 loaded femurs, n=2 control femurs). After applied loading, bones were dissected 
free of soft tissues. The lateral epiphysis of each femur was isolated using a low-speed 
precision saw (IsoMet Low Speed Saw, Buehler, Lake Bluff, Illinois USA). 
Microdamage was stained with a radiopaque marker (lead uranyl acetate) using a 
previously described protocol [38, 39]. Three-dimensional images of the specimens 
were collected using microcomputed tomography (Versa 520, Carl Zeiss AG, 
Oberkochen, Germany) in air with energy of 120 kVp and an isotropic voxel size of 
10 μm. After imaging, a cylindrical volume of interest 3.7 mm in diameter and 3.7 mm 
high, located 500 microns away from the surface of the loading core was used for 
analysis. A three-dimensional Gaussian filter (sigma=1.2, support 1) was applied to 
the images, and an automated global threshold based on the image mean intensity 
value was used to segment bone from soft tissue (ImageJ 1.50d, National Institute of 
Health, USA). Microdamage stained with lead uranyl acetate was segmented from 
bone using a manual threshold; non-specific surface staining and damage objects less 
than 10,000 μm3 were removed as noise (approximately the volume of 25 osteocyte 
lacunae, see [38] for further justification of image processing). The volume of tissue 
microdamage was measured per unit bone volume (damage volume fraction, DV/BV). 
No signs of overt failure (macroscopic fractures or discontinuities in the 
loading displacement curve) were observed during cyclic loading (Supplemental 
Figure 2). Samples loaded in situ displayed substantial tissue microdamage, while 
control limbs had negligible amounts of stained microdamage (damage volume 
fraction: Loaded 5.7 ± 3.1% vs. Control 0.6 ± 0.8%, mean ± SD, p = 0.01, see 
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Supplementary Figure 3).  
 
Figure 5.5. A cyclic loading regimen of 0.2-2.0 MPa in compression at 2 Hz 
frequency for 10,000 cycles generated tissue microdamage in cancellous bone without 
causing overt fracture. (A) Histological image of cancellous bone (bone=blue) in the 
rabbit distal femur stained for microdamage with calcein green and location of applied 
loading indicated. (B) An enlarged image of the boxed region displays the 
microdamage (stained with calcein green, indicated by green arrows).  
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Figure 5.6. Peak-to-peak displacement during cyclic loading in for all five limbs 
loaded in situ. No signs of overt failure, indicated by a rapid increase in deformation, 
were observed.  
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Figure 5.7. Three-dimensional reconstructions of cancellous bone and microdamage 
(pink) from in situ loading are shown for (A) a loaded limb and (B) control limb. (C) 
Loaded specimens (n=5) had a greater damage volume fraction than controls (n=2). 
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CHAPTER 6                                                      
SUMMARY AND FUTURE DIRECTIONS 
 
Bone loss following increased bone remodeling impairs the mechanical 
performance of cancellous bone and increases fracture risk. Cancellous bone strength 
is only partially explained by changes in bone mass, suggesting that factors 
independent of bone mass contribute to cancellous bone mechanical performance. The 
role that aspects of bone quality, including resorption cavity size, trabecular 
morphology and tissue composition, have on cancellous bone strength was unclear. 
Here, I investigated how bone quality was changed by altering bone remodeling 
through pharmaceutical treatment and how aspects of bone quality affected the 
accumulation of microdamage in cancellous bone. Finally, I investigated how bone 
remodeling responded to microdamage in a rabbit model for bone marrow lesions. 
6.1. Aim 1 Summary 
We investigated how treatment with anti-resorptive agents influenced the size 
of individual resorption cavities in a rodent model of estrogen depletion. We found 
that anti-resorptive treatment was associated with reduced resorption cavity size. The 
change in resorption cavity size was expected to reduce the stress concentration effect 
of cavities and was proposed as a potential mechanism through which treatment with 
anti-resorptive agents could reduce fracture risk greater than expected from changes in 
BMD. 
6.2. Aim 2 Summary 
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We analyzed how treatment with sclerostin antibody modified the rod- or 
plate-like morphology and orientation of trabeculae in a cynomolgus monkey model. 
We found that sclerostin antibody treatment increased bone formation in a way that 
converted rod-like trabeculae into plate-like trabeculae. Sclerostin antibody also 
increased the thickness of both rods and plates regardless of trabecular orientation 
leading to an increase in apparent stiffness determined from finite element models. 
However, the improvements in the elastic mechanical performance were well 
explained by changes in bone volume. 
6.3. Aim 3 Summary 
We examined how resorption cavities and tissue composition (AGEs) 
influenced where microdamage formed and propagated following cyclic mechanical 
loading. We found that microdamage formed preferentially in the central regions of 
trabeculae, where the concentration of AGEs was greatest and away from resorption 
cavities on the more ductile trabecular surfaces. The preferential location of 
microdamage at trabecular centers may aid in deformation recovery following loading. 
6.4. Aim 4 Summary 
We evaluated the bone remodeling response to microdamage using an in vivo 
loading model that included the creation of BMLs in subchondral cancellous bone. We 
found an increase in bone resorption as measured by eroded surface in response to 
microdamage created by loading. The load-induced microdamage and subsequent 
increased bone resorption corresponded to regions where BMLs were created. 
6.5 Thesis Synthesis 
  
181 
 
 The overall goal of the work described here was to understand how changes in 
bone remodeling influenced cancellous bone strength in ways not attributable to bone 
mass. Anti-resorptive treatments for osteoporosis function primarily to decrease bone 
remodeling. Anti-resorptive agents decrease fracture risk beyond what could be 
attributed to changes in bone mass alone. We hypothesized that one major mechanism 
through which anti-resorptive treatments achieve a disproportionately large reduction 
in fracture risk was by reducing the size of resorption cavities. In Aim 1, we found that 
indeed anti-resorptive treatment did reduce the size of resorption cavities. Finite 
element models of cancellous bone with resorption cavities indicate that cavities act as 
stress risers in bone and that deeper cavities increase have an even greater stress 
concentration effect [1-4]. Consequently, resorption cavities should act as sites for 
microdamage initiation. In Aim 3, we directly tested the hypotheses that 1) resorption 
cavities would promote microdamage initiation and propagation following fatigue 
loading and 2) that deep resorption cavities would promote microdamage to a greater 
extent than small cavities. We found that in fact resorption cavities did not promote 
microdamage. Consequently, it is unlikely that resorption cavities play a significant 
role in influencing bone strength or fracture risk beyond what can be attributed to a 
loss in bone volume or through fenestration of trabeculae. Our results from Aim 3 
indicate that cancellous bone tissue composition plays a greater role in determining 
where microdamage will form than resorption cavities. Microdamage formed 
preferentially in the central regions of the trabeculae, where the tissue was older and 
had accumulated a greater concentration of AGEs. 
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 Bone resorption in response to microdamage may influence the progression of 
osteoarthritis. In Aim 4, we developed an in vivo loading model to create 
microdamage in subchondral cancellous bone. We found that increased bone 
resorption in response to microdamage accompanied the development of bone marrow 
lesions in subchondral cancellous bone. Our findings are consistent with a proposed 
pathway in which microdamage created by loading initiates an increase in bone 
resorption to repair damage. One potential molecular mechanism involves TGF-β. 
TGF-β in bone matrix is released by osteoclastic resorption [5] and subsequently 
influences the formation of nestin+ mesenchymal stem cell (MSC) clusters. These 
MSC clusters result in increased angiogenesis, aberrant bone formation, and bone 
marrow lesions prior to cartilage degeneration [6]. The direct role of bone marrow 
lesions in cartilage degeneration is unclear but may involve the disruption of bone and 
cartilage crosstalk by acting as a perfusion abnormality [7]. 
 Next we investigated how the rod- and plate-like morphology and orientation 
of individual trabeculae may influence bone strength independent of bone mass. 
Anabolic treatments of osteoporosis could increase bone formation to such an extent 
that they could change the shape the individual trabeculae from rod to plates or even 
create new trabeculae. In Aim 2, we tested the hypotheses that sclerostin antibody 
could transition trabecular rods into trabecular plates and create new trabecular 
connections. While we did not observe any newly formed trabeculae, we did observe 
rods that transitioned into plates due to sclerostin antibody treatment. We also 
observed a thickening of the rods that did not transition to plates. The improvement in 
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trabecular morphology did improve the elastic mechanical properties of cancellous 
bone as predicted by finite element models; however, the improvements were almost 
entirely explained by changes in bone volume. While it does not appear that trabecular 
morphology or orientation influenced the pre-yield mechanical properties of 
cancellous bone independent of bone volume, the rod- and plate-like structure and 
orientation of trabeculae may be more influential in cancellous bone loaded in fatigue. 
Results from a recent study that included specimens from Aim 3 showed that the 
thickness of rod-like trabeculae influences how much microdamage forms in 
cancellous bone for a given strain. Additionally, morphology and orientation of 
trabeculae appear to influence when microdamage forms as a function of fatigue life 
with rod-like trabeculae aligned in the transverse direction failing preferentially in 
early fatigue and axially-aligned plate-like trabeculae failing primarily during late 
fatigue [8]. 
6.6. Future Directions 
6.6.1. Three-dimensional spatial correlation between cancellous bone tissue 
composition and microdamage 
In Aim 3, we found that microdamage formed preferentially in the central 
regions of trabeculae where the concentration of AGEs is greatest. It is unclear; 
however, which aspect of tissue composition, AGEs or local tissue degree of 
mineralization, were primarily responsible for microdamage formation. Both AGEs 
and local tissue degree of mineralization increase as tissue ages, and are found 
preferentially in the central regions of cancellous bone where bone turnover is less 
likely to occur. Understanding which aspects of bone tissue composition drive 
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microdamage formation are important in that it could help us understand the 
mechanism of bone failure and potentially develop therapeutic solutions that target 
specific aspects of bone tissue composition. Furthermore, it would provide further 
insight into how diseases that modify tissue composition like diabetes mellitus modify 
the biomechanical performance of bone. 
I propose the following research study to more fully understand how local 
tissue degree of mineralization and AGEs influence where microdamage forms and 
propagates. Specimens of cancellous bone would be obtained from cadaver vertebrae 
and divided into one of two groups. One group would receive ribosylation to create a 
high concentration of AGEs homogenously distributed throughout the cancellous bone 
structure [9, 10], and the other group would serve as a control. First, all specimens 
would be evaluated with SrμCT to identify the bone mineral density distribution 
(BMDD) at each voxel. Cohort-1 of each group would be evaluated for AGEs using 
the fluorometric approach detailed in Aim 3 and registered to the three-dimensional 
BMDD images; Cohort-2 would receive cyclic mechanical loading until failure to 
create microdamage. Next, three-dimensional spatial correlation between 
microdamage created from fatigue loading and regions of high mineral content from 
the BMDD images would be examined for the two groups.  
The proposed study would allow us to determine if microdamage forms 
preferentially in regions with the greatest BMDD or if AGEs matter more in directing 
microdamage formation. If ribosylation of cancellous bone changes the damage 
formation pattern such that damage does not form in the central regions of trabeculae 
  
185 
 
in the ribosylated group, it would indicate that AGEs, rather than BMDD 
preferentially determine where microdamage forms. Whereas, if damage still forms 
where  BMDD is highest, it would indicate that local tissue degree of mineralization 
plays a stronger role in direct damage formation. An analysis testing the spatial 
correlation between resorption cavities and microdamage in the ribosylation group 
could also yield interesting results. If the lack of AGEs on trabecular surfaces were the 
reason why most microdamage did not form near resorption cavities, we would expect 
a stronger spatial correlation between cavities and microdamage if AGEs were 
distributed homogenously because resorption cavities are geometric stress risers. 
6.6.2. Biomimetic open-cell foam with material heterogeneity 
In Aim 3, we observed that material heterogeneity in cancellous bone directed 
microdamage toward trabecular regions that are least likely to experience large 
permanent deformation and away from regions that are most likely to experience large 
deformation or contain surface flaws. We speculated that the location of microdamage 
would allow the cancellous bone structure to recover more deformation than if 
trabeculae had accumulated damage at surfaces, and, indeed, cancellous bone has been 
shown can recover 61-94% of applied deformation [11-13] caused by loading beyond 
the ultimate strain. An open-cell foam with similar patterns of material heterogeneity 
may exhibit increased deformation recovery as well, enhancing the structure’s 
mechanical function after overt failure. 
 I propose the following research project to test the idea that material 
heterogeneity in bone leads to improved deformation recovery. First, I would 
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implement additive manufacturing to create high-resolution structures with the 
microstructure of cancellous bone and heterogeneous material properties [14, 15]. For 
one group, the structures would be composed of harder, more brittle materials in the 
inner regions of each trabecula and more ductile regions on trabecular surfaces. A 
second group would receive the same two materials, except that the brittle material 
would be on the surfaces and the ductile material would be used in the central region. 
A third group would be printed with only one material. The microstructures of the 
specimens would be based on microCT images of specimens from Aim 3, and each 
specimen would be printed for all three groups. Material selection should be devised 
to maintain a similar mass for the same specimen in each group. Next, we would 
perform fatigue loading on the three groups in a similar fashion to Aim 3, with 
particular emphasis being placed on measurements of deformation recovery. Using the 
proposed three groups, we would be able to observe how changes in material 
heterogeneity in specimens with identical geometry would influence deformation 
recovery. An alternative strategy would be to create 3D printed bone structures from 
metal and use either surface annealing to increase surface ductility or surface 
hardening to decrease surface ductility. 
6.6.3. In vivo rabbit loading to study bone marrow lesion progression and spatial 
correlation between microdamage, bone remodeling and bone marrow lesions 
In Aim 4, we established an animal model for bone marrow lesions. Bone 
marrow lesions are associated with pain, cartilage degeneration and an increased risk 
of total joint replacement [16-18]. Understanding the mechanisms through which bone 
marrow lesions form and progress would aid in our understanding of early 
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osteoarthritis progression since bone marrow lesions are an early indicator of 
osteoarthritis. Identifying effective treatment options for established bone marrow 
lesions are clinically significant as well since bone marrow lesions may actually 
contribute to osteoarthritis progression, and an effective treatment for a bone marrow 
lesion may also limit or even reverse osteoarthritis progression.  
I propose the following experiments that further test the idea that BML 
creation is stimulated by bone resorption in response to mechanically-induced 
microdamage and to evaluate potential treatment options for existing BMLs. For the 
first experiment, rabbits would be divided into four treatment groups two weeks prior 
to loading: TGF-β inhibitor treatment [6], bisphosphonate treatment, an anti-
angiogenesis treatment, and control. In vivo loading would be applied to the right 
distal femur of all animals; as an additional control, contralateral limbs would receive 
implants but no loading. One cohort of animals from each group would be sacrificed 
bi-weekly to characterize bone remodeling and how much microdamage exists at a 
given time point. Animals would also be evaluated with MRI at bi-weekly intervals to 
identify and measure bone marrow lesions and changes to articular surfaces. 
The rationale behind the treatment groups is as follows: TGF-β has been 
identified as a key mechanistic factor from which microdamage leads to cartilage 
degeneration. TGF-β is released by bone resorption leading to the recruitment of 
mesenchymal stem cell clusters, subsequent increases in bone formation, BMLs and 
eventually cartilage degeneration. A TGF-β inhibitor is not expected to impair 
microdamage repair (and may actually increase resorption) but should decrease the 
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bone formation/MSC recruitment response that accompanies damage repair, thereby 
inhibiting BML formation. Anti-resorptive treatment should inhibit resorption 
stimulated by microdamage, either preventing or limiting the pathway that leads to 
BML formation. Furthermore, anti-resorptive treatment decreases resorption cavity 
size and may indirectly inhibit release of TGF-β by reducing the volume of bone 
resorbed at each remodeling site. Increases in angiogenesis have been observed in 
biopsies of BMLs, suggesting that an angiogenesis inhibitor may inhibit BML 
formation. Using MR imaging, we can obverse how the three approaches may prevent 
(or exacerbate) BML formation, modify the bone remodeling response to 
microdamage, and lead to differences in cartilage damage. 
Next we would perform a new set of experiments on animals with established 
bone marrow lesions. The right limbs of all animals would receive in vivo loading to 
create BMLs. Upon confirmation of a BML two weeks following loading, animals 
would be assigned into one of four groups, a bisphosphonate treatment to inhibit bone 
remodeling, an angiogenesis inhibitor to inhibit vascularity, chondroitin sulphate, a 
proposed therapeutic for bone marrow lesions [19], and a final group that would 
receive a subchondroplasty the area of a bone marrow lesion [20]. Subchondroplasty is 
a new surgical technique to decrease bone marrow lesion size. Bone marrow lesion 
size and changes to articular cartilage would be evaluated bi-weekly following 
treatment using MRI. Tissue from the bone marrow lesion would then be evaluated for 
bone remodeling, microdamage, and mechanical performance using mechanical 
testing to observe how proposed treatment options affect the cancellous bone. 
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APPENDIX 
 
Aim2 Creation of FE model with boundary conditions to run in Abaqus 
Purpose: The following protocol is used to create and run Abaqus input files based on 
stack of images of bone (tiff format). Following creation of a basic mesh using 
tiff_stack_to_aba_inp.m, the user can create boundary conditions on the top and 
bottom surfaces using a bash script. 
1. Create binary tiff stack of images of cancellous bone. Use connective 
component analysis to ensure that all cancellous bone is connected. 
2. Create an input file (inp.) from the tiff stack using Run 
tiff_stack_to_aba_inp.m in MATLAB 
a. Select MicroCT Images Folder.....what folder contains the image stack 
b. Select folder to store inp.....what folder do you want to store the input 
file 
c. What would you like to name this abaqus input file?...... input file name 
d. What is the voxel size for this image in mm for this tiff stack?.....input 
voxel size in mm 
e. What is the threshold value for this tiff stack?... for binary pick 
anything greater than 0 and less than 255 
3. Open Cygwin Terminal and change working directly (cd) to folder with input 
files (Example below) 
Jonathan Matheny@BIOMECH-11 ~ 
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$ cd /cygdrive/k/tiffstack/Input_Files/ 
(drive K and subfolders tiffstackInput_Files) 
4. Create new folder to store complete input files (Input _full is example below) 
and change directory to it 
a. Store mkinp.awk in this newly created folder 
5. Type the following command line in Cygwin to run mkinp.awk. Mkinp will 
create boundary conditions, material properties, etc. for the model 
Jonathan Matheny@BIOMECH-11 /cygdrive/k/tiffstack/Input_Files/Input_full 
$ for file in ../*inp; do echo $file; ./mkinp.awk $file; done 
The script will run on any input file in the folder, and the output input file(s) will have 
the attachment text “_full”. 
6. Move full input files to complete input file folder (Input_full) 
Jonathan Matheny@BIOMECH-11 /cygdrive/k/tiffstack/newtest/Input_full 
$ mv ../*full.inp . 
7. Run Abaqus to create FE models for the input files by inputing the following 
lines of text, one line at a time  
Jonathan Matheny@BIOMECH-11 /cygdrive/k/tiffstack/newtest/Input_full 
$ for file in *.inp;do 
> echo $file 
> done 
> /cygdrive/c/SIMULIA/Abaqus/Commands/abaqus.bat interactive cpus=3 job=$file 
Abaqus will run any input file in this folder. 
If you need to kill the operation, do so using task manager, finding the specific process 
Abaqus is using and ending it. 
Mkinp.awk will apply boundary conditions (fixed bottom boundary and compression 
to top boundary in the z-dimension. 
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#!/bin/awk -f 
 
 
# (for pre-generated aba input files, "," is the field separator) 
 
BEGIN {FS=",";mode="none"; maxz=-1e10; minz=1e10 
 
  # find max and min z since there's round off differences 
 
  # the current input file 
  finp= ARGV[ARGC-1] 
 
  # output file 
  fout = substr(finp,1,length(finp)-4)"_full.inp" 
 
  # loop through it checking z values 
  while (getline < finp > 0) { 
    if ($0 ~ /\*/) {mode="none"} 
 
    if (mode=="node") { 
      if ($4 > maxz) { 
        maxz=$4 
      } 
      if ($4 < minz) { 
        minz=$4 
      } 
    } 
 
    if ($0 ~ /NODE/) {mode="node"} 
  } 
} 
 
 
# let us know we don't have nodes to process 
/\*/ {mode="none"} 
 
{ 
 
if (mode=="node") { 
  # check if they are in the max or min sets 
  if ($4 == maxz) maxn[$1]=$1 
  if ($4 == minz) minn[$1]=$1 
 
  # we want to echo the input file 
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  print >fout 
} 
# not a node to process 
else { 
  # we want to echo the input file 
  print >fout 
} 
 
} 
 
# tell us that the next lines are nodes to process 
/NODE/ {mode="node"} 
 
 
END { 
 
  print "**" >fout 
  print "*NSET, NSET=top" >fout 
  n = 0 
  # write out all the nodes in the top group, eight to a line 
  for (i in maxn) { 
    n++ 
    if (n < 9) { 
      printf ("%9d,",i) >fout 
    } 
    else { 
      printf ("\n%9d,",i) >fout 
      n=1 
    } 
  } 
  printf "\n" >fout 
     
  print "*NSET, NSET=bottom" >fout 
  n = 0 
  # write out all the nodes in the bottom group, eight to a line 
  for (i in minn) { 
    n++ 
    if (n < 9) { 
      printf ("%9d,",i) >fout 
    } 
    else { 
      printf ("\n%9d,",i) >fout 
      n=1 
    } 
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  } 
  printf "\n" >fout 
  print "**" >fout 
 
  # now write out props and link to the elements 
  # it is assumed that the elements are defined w/ ELSET=PROP1 
  print "*MATERIAL,NAME=MATPROP1" >fout 
  print "*ELASTIC,TYPE=ISO" >fout 
  print "10000,0.3" >fout 
  print "**" >fout 
 
  # link the prop to the element set 
  print "*SOLID SECTION,ELSET=PROP1,MATERIAL=MATPROP1" >fout 
  print "**" >fout 
 
  # Hmmm, don't need to fix rigid motion?? 
 
  # set the bottom as a global boundary condition (=0 disp) 
  print "*BOUNDARY" >fout 
  print "bottom,  3,,     0." >fout 
  print "**" >fout 
 
  # write out the step control 
  print "*STEP, PERTURBATION" >fout 
  print "*STATIC" >fout 
  print "**" >fout 
 
  # imposed displacement of -0.02 (1% of core height) 
  print "*BOUNDARY" >fout 
  print "top, 3,,   -0.02" >fout 
  print "**" >fout 
 
  # by specifying nothing, you should get default output in .odb 
 
  # ask for reaction forces in the .dat file 
  print "*NODE PRINT, NSET=bottom, FREQ=1" >fout 
  print "RF" >fout 
  print "**" >fout 
 
  # and we're done 
  print "*END STEP" >fout 
} 
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 Mkinpx.awk will apply boundary conditions (fixed bottom boundary and 
compression to top boundary in the x-dimension. The material properties and amount 
of displacements are highlighted in yellow. 
 
#!/bin/awk -f 
 
 
# (for pregenerated aba input files, "," is the field separator) 
 
BEGIN {FS=",";mode="none"; maxz=-1e10; minz=1e10 
 
  # find max and min z since there's roundoff differences 
 
  # the current input file 
  finp= ARGV[ARGC-1] 
 
  # output file 
  fout = substr(finp,1,length(finp)-4)"_full.inp" 
 
  # loop through it checking z values 
  while (getline < finp > 0) { 
    if ($0 ~ /\*/) {mode="none"} 
 
    if (mode=="node") { 
      if ($4 > maxz) { 
        maxz=$4 
      } 
      if ($4 < minz) { 
        minz=$4 
      } 
    } 
 
    if ($0 ~ /NODE/) {mode="node"} 
  } 
} 
 
 
# let us know we don't have nodes to process 
/\*/ {mode="none"} 
 
{ 
 
if (mode=="node") { 
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  # check if they are in the max or min sets 
  if ($4 == maxz) maxn[$1]=$1 
  if ($4 == minz) minn[$1]=$1 
 
  # we want to echo the input file 
  print >fout 
} 
# not a node to process 
else { 
  # we want to echo the input file 
  print >fout 
} 
 
} 
 
# tell us that the next lines are nodes to process 
/NODE/ {mode="node"} 
 
 
END { 
 
  print "**" >fout 
  print "*NSET, NSET=top" >fout 
  n = 0 
  # write out all the nodes in the top group, eight to a line 
  for (i in maxn) { 
    n++ 
    if (n < 9) { 
      printf ("%9d,",i) >fout 
    } 
    else { 
      printf ("\n%9d,",i) >fout 
      n=1 
    } 
  } 
  printf "\n" >fout 
     
  print "*NSET, NSET=bottom" >fout 
  n = 0 
  # write out all the nodes in the bottom group, eight to a line 
  for (i in minn) { 
    n++ 
    if (n < 9) { 
      printf ("%9d,",i) >fout 
  
200 
 
    } 
    else { 
      printf ("\n%9d,",i) >fout 
      n=1 
    } 
  } 
  printf "\n" >fout 
  print "**" >fout 
 
  # now write out props and link to the elements 
  # it is assumed that the elements are defined w/ ELSET=PROP1 
  print "*MATERIAL,NAME=MATPROP1" >fout 
  print "*ELASTIC,TYPE=ISO" >fout 
  print "10000,0.3" >fout 
  print "**" >fout 
 
  # link the prop to the element set 
  print "*SOLID SECTION,ELSET=PROP1,MATERIAL=MATPROP1" >fout 
  print "**" >fout 
 
  # Hmmm, don't need to fix rigid motion?? 
 
  # set the bottom as a global boundary condition (=0 disp) 
  print "*BOUNDARY" >fout 
  print "bottom,  3,,     0." >fout 
  print "**" >fout 
 
  # write out the step control 
  print "*STEP, PERTURBATION" >fout 
  print "*STATIC" >fout 
  print "**" >fout 
 
  # imposed displacement of -0.02 (1% of core height) 
  print "*BOUNDARY" >fout 
  print "top, 3,,   -0.02" >fout 
  print "**" >fout 
 
  # by specifying nothing, you should get default output in .odb 
 
  # ask for reaction forces in the .dat file 
  print "*NODE PRINT, NSET=bottom, FREQ=1" >fout 
  print "RF" >fout 
  print "**" >fout 
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  # and we're done 
  print "*END STEP" >fout 
   
} 
 
Aim 3: Operating the MTS Material Testing Machine – Cyclic Loading 
This protocol describes how to operate the MTS machine located in Upson 148 to test 
endcapped cancellous bone cores. The test consists of 10 preconditioning cycles to 
0.2% compressive strain followed by two bouts of cyclic compressive loading. 
1. Remove endcapped specimen from refrigerator and allow to thaw for a 
minimum of 30 minutes before testing (Perform steps 2-11 while specimen 
thaws) 
2. Login to MTS computer. (Station Manager should be opened the day before 
testing with configuration file Floor.cfg, parameter set 100 lbf. Load cell Aim 
4) 
3. Attach upper and lower fastening chucks to MTS mechanical testing rig 
4. Connect Hernandez extensometer (Number:51-191-508) to MTS testing 
machine On screen Signal Auto Offset, select Clear Offsets 
5. Calibrate external load cell using signal conditioner.  
6. On screen Station Manager: 
a. Check Exclusive Control 
b. Reset Interlock 1 
c. Turn on hydraulics in software 
i. Hit top button, wait until solid green 
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ii. Hit lower yellow button (two bars) followed by lower green 
button (three bars) 
7. Turn on physical hydraulics by flipping switch to low (counterclockwise) and 
then to high (clockwise) 
8. On screen Signal Auto Offset, select Clear Offsets 
9. On screen Manual Command, select enable manual command and set 
displacement to 0.000 mm, deselect enable manual command 
10. On screen Station Manager, run function generator for 30 minutes (0.1 Hz, 40 
mm amplitude) then stop 
11. Raise piston head up so that endcapped specimen can be placed in MTS testing 
machine (See step 9 for displacement of piston head) 
12.  After thawing, use the following procedure to attach a hydraulically sealed 
chamber to specimen and attach specimen to MTS testing machine 
a. Cut off pinky finger from small sized nitrile glove and cut off twice the 
length of the exposed specimen from the finger-tip region of the glove 
(allows for the glove piece to slip over the specimen) 
b. Before the specimen is fastened to the protective block, slide glove 
piece onto endcap that will be fastened to bottom chuck, place O-rings 
on both end-caps with minimal force on specimen 
c. Fasten specimen to protective block 
d. Clamp bottom endcap to bottom chuck 
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e. Using adjustable plate attached to bottom chuck, align bottom chuck 
with top chuck, tighten adjustable plate screws 
f. On screen Signal Auto Offset, select Auto Offset  
g. Tighten upper chuck to upper endcap 
h. Remove protective block from specimen 
i. Record Preload value in terms of volts and convert to force units (in N) 
using the equation Force=43.164 *V -0.2373 
j. If the specimen appears to be misaligned (as signified by a high preload 
value of over 20 N), repeat sub steps d-h 
k. Pull up glove so that the glove span over both end-caps, move the O-
ring attached to bottom endcap near the upper edge of the endcap 
l. Use syringe to add 1 mL of PBS solution to the specimen encased 
inside the glove 
m. Move O-ring on upper endcap over the glove and move to lower edge 
of the endcap 
n. With a scalpel, remove glove parts to the outside of the two O-rings 
and dry with Chem-Wipes (this is to ensure the hydration chamber fits 
within in the extensometer) 
13.  Attach extensometer to specimen and remove pin from extensometer (watch 
strain reading to ensure the value does not drift too much) 
14. On screen Signal Auto Offset, auto offset value for axial strain 
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15. Open Multipurpose elite software, select fileOpen Test and select 
AIM4_Preconditioning_100lbf 
16. Click “New Test Run”Click “Add New”Enter specimen name and press 
“OK” twiceEnter pre-measured values for specimen length, diameter, and 
exposed length. 
17. Double check to make sure extensometer pin is removed, MTS is in 
displacement mode, and alignment plate is tightened.  
18. Press Run, preconditioning test should complete in approximately 5 seconds. 
Record effective length, area, and initial modulus from variable summary page, 
save test 
19.  Using the excel sheet Emod.xlsx, calculate the initial modulus that will be 
used for the subsequent bouts of cyclic loading (should be close in value to the 
modulus calculated by MTS) 
20. In the Multipurpose elite software, select fileOpen Test and select 
AIM4_Fatigue_Part 1_100lbf 
21. Click “New Test Run”Click “Add New”Enter specimen name and press 
“OK” twiceEnter pre-measured values for specimen length, diameter, and 
exposed length and initial modulus calculated from Emod.xlsx. 
22. Double check to make sure extensometer pin is removed, MTS is in 
displacement mode, and alignment plate is tightened.  
23. Press Run, place hand near emergency stop. Test will need to be manually 
stopped by the user once the value for stainrate10 exceeds +15 or appears to be 
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entering into the tertiary phase. The test will automatically stop if the value for 
strain exceeds 2%. 
24. Once the test has stopped, take a screen shot of the runtime display and save in 
a PowerPoint file. Save test run. 
25. Make sure MTS is in displacement mode.  
26. Fasten protective block to specimen, remove from MTS testing machine, and 
submerge specimen in 0.5 mM solution of xyenol orange staining for 2 
hours store in refrigerator 
27. After staining, perform three rinses (10 minutes each) in deionized water 
28. Repeat Steps 11-14 to attach a hydraulically sealed chamber to the specimen, 
attach the specimen to MTS mechanical testing rig, and attach extensometer to 
the specimen 
29. In the Multipurpose elite software, select fileOpen Test and select 
AIM4_Preconditioning_100lb_part 2(This preconditioning only runs for 3 
cycles). Click save 
30. In the Multipurpose elite software, select file Open Test and select 
AIM4_Fatigue_Part 2_100lbf 
31. Click “New Test Run”Click “Add New”Enter specimen name and press 
“OK” twiceEnter pre-measured values for specimen length, diameter, and 
exposed length and initial modulus calculated from Emod.xlsx. 
32. Double check to make sure extensometer pin is removed, MTS is in 
displacement mode, and alignment plate is tightened.  
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33. Press Run, place hand near emergency stop. Test will stop automatically once 
the value for stain exceeds 4%. 
34. Once the test has stopped, take a screen shot of the runtime display and save in 
a powerpoint file. Save test run. 
35. Make sure MTS is in displacement mode. 
36. Fasten protective block to specimen, remove from MTS testing machine, and 
submerge specimen in 0.5 mM solution of Calcein staining for 2 hours store 
in refrigerator 
37. After staining, perform three rinses (10 minutes each) in deionized water 
38. Using the Isomet 1000 saw, remove the exposed portion of the specimen, store 
specimen in 70% EtOH, and submerge end-caps in acetone for at least 24 
hours. 
39. Close out of Multipurpose elite software 
40. Lower piston head to lowest position 
41. Turn off the hydraulics in the software 
42. Turn off the real hydraulics by switching to low and then pressing the red 
button 
43. Exit station manager (use file Exit, not the X button 
44. Log off computer 
45. Sanitize area and surfaces with 10% bleach for 10 minutes, wash with water 
and dry 
Aim 3: Derivation for Calculating Tissue Modulus for Aim 3 Specimens using 
Finite Element Models and Apparent Modulus from Mechanical Testing 
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݀ ൌ 0.09	݉݉						              Displacement applied to top face of each sample in 
Finite Element Model in negative z-direction 
݄ ൌ 13.85݉݉								               Height of each sample in Finite Element Model 
ߝ஺ିிா ൌ ௗ௛ ൌ 0.0064                Apparent applied strain to each sample in 
Finite Element Model. Since both h and d are constant among each sample, εA-FE is 
constant among samples 
ܧ஺ିா௫௣                Experimentally measured Apparent Young’s 
Modulus found using a preconditioning loading cycle. The value is different for each 
sample 
ߝ஺ିா௫௣ ൌ ఙಶೣ೛ாಲషಶೣ೛ ൌ 0.0039Experimental Apparent applied strain to each sample. 
σExp chosen such that εA-Exp is constant among samples 
ߪா௫௣                 Apparent Stress applied to each sample. 
σExp is selected to satisfy the equation σExp=εA-Exp *EA-Exp 
Since both the apparent strain applied experimentally (εA-Exp )and apparent strain 
applied in the Finite Element Model (εA-FE) are constant among samples, the strain 
distributions among samples are comparable The Finite Element Model chosen is 
appropriate to approximate the local strain distributions created experimentally by 
loading.  
While the Tissue Modulus was assumed to be homogeneous and held constant at 10 
Gpa in the Finite Element Models, the actual average tissue modulus of the bone was 
not known. The following derivation will allow the determination of average tissue 
modulus. 
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ܧ்௜௦௦௨௘ିிா ൌ 10	ܩܲܽ  Tissue Modulus chosen for each sample of the finite 
element model, the same value for tissue modulus was chosen for each sample 
ܣிா ൌ 5.027 ൈ 10ିହ݉ଶ Cross-sectional area for each sample given that each 
sample had a radius of 4 mm, found using the equation A=π*r2. 
ܨிா      Total Reaction Force was determined from 
the finite element model for each sample (in N). The value is different for each 
sample. 
ߪிா ൌ ிಷಶ஺ಷಶ    Apparent Stress was applied to each sample in 
the finite element model (in Pa). The value is different for each sample. 
ܧ஺ିிா ൌ ఙಷಶఌಲషಷಶ    Apparent Young’s Modulus was derived for each 
sample for the finite element model (in Pa). The value is different for each sample. 
ܧ்௜௦௦௨௘ିா௫௣ ൌ ܧ஺ିா௫௣ ாಲషಷಶா೅೔ೞೞೠ೐షಷಶൗ  The experimentally derived average tissue 
modulus was determined from the using parameters from finite element model and 
from the experimentally measured EA-Exp. 
The local tissue stresses from the finite element model were calculated using the 
constant finite element tissue modulus of 10 GPa. Since a linear element finite element 
model was used. The derived experimental tissue modulus can be used to scale local 
tissue stresses to the correct magnitude using the scale factor ratio ETissue-Exp/ ETissue-FE. 
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Aim 4: Histological Sections of the distal Rabbit Femur Visualized using Confocal 
Microscopy 
 
 
Rabbit 74 Loaded Limb-Maximum Intensity Projection Image 
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Rabbit 74 Control Limb-Maximum Intensity Projection Image 
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Rabbit 75 Loaded Limb-Maximum Intensity Projection Image 
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Rabbit 75 Control Limb-Maximum Intensity Projection Image 
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Rabbit 76 Loaded Limb-Maximum Intensity Projection Image 
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Rabbit 76 Control Limb-Maximum Intensity Projection Image 
